var title_f2_57_2960="Ascending aortic dissection on echocardiogram";
var content_f2_57_2960=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ascending aortic dissection on echocardiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 290px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Modified long axis view shows a proximal dissection of the aortic root (Ao), with a flap extending to the aortic valve (V). This aortic pathology is seen by imaging the ascending aorta one interspace above the usual long axis precordial window.",
"    <div class=\"footnotes\">",
"     LA: left atrium; LV: left ventricle.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_57_2960=[""].join("\n");
var outline_f2_57_2960=null;
var title_f2_57_2961="What's new in endocrinology and diabetes mellitus";
var content_f2_57_2961=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   What's new in endocrinology and diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/57/2961/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/57/2961/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/57/2961/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/57/2961/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     DIABETES MELITUS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Screening for diabetes mellitus",
"    </span>",
"   </p>",
"   <p>",
"    There are few trials evaluating the benefits of screening for type 2 diabetes. In one recent trial, 33 general practices in the United Kingdom were randomly assigned to screening followed by intensive multifactorial treatment of people diagnosed with diabetes, screening followed by routine care of diabetes, and a no-screening control group [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2961/abstract/1\">",
"     1",
"    </a>",
"    ]. Individuals were selected for participation in the trial based upon an increased risk score for diabetes. After a median follow-up of 9.6 years, there was no difference in overall mortality between the screening and control groups. Limitations of this trial included a low overall prevalence of newly diagnosed diabetes (3 percent of screened population) and a relatively brief follow-up period, given the long-term complications of diabetes require more than a decade of diabetes to develop, with morbidity or mortality associated with the complications requiring substantially more time. Additional trials examining morbidity and quality of life issues between screen-detected diabetes and diagnosis through routine clinical care are needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2312?source=see_link&amp;anchor=H2377257#H2377257\">",
"     \"Screening for diabetes mellitus\", section on 'Effectiveness of early detection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     FEMALE REPRODUCTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Long-term use of postmenopausal hormone therapy",
"    </span>",
"   </p>",
"   <p>",
"    The United States Preventive Services Task Force (USPSTF) has published an updated meta-analysis of postmenopausal hormone therapy (nine trials) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2961/abstract/2\">",
"     2",
"    </a>",
"    ]. Results were largely based upon the two Women's Health Initiative trials, and the mean age of subjects was &gt;60 years. Estrogen plus progestin, as well as&nbsp;unopposed estrogen, decreased fracture risk but increased&nbsp;the risk for stroke, venous thromboembolic events, and gallbladder disease. Estrogen plus progestin increased risk for breast cancer, but unopposed estrogen decreased breast cancer risk. Based upon these data, the USPSTF continues to recommend against the use of both combined estrogen and progestin and unopposed estrogen for prevention of chronic conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2961/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. However, they note that this recommendation does not apply to women considering&nbsp;hormone therapy for relief of menopausal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2961/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link&amp;anchor=H91121219#H91121219\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\", section on 'Indications for treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     OBESITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Green tea and management of obesity",
"    </span>",
"   </p>",
"   <p>",
"    Catechins and caffeine in green tea are believed to increase energy metabolism, and green tea has been promoted as an aid in weight loss.&nbsp;In a 2012 meta-analysis of trials comparing green tea preparations with a control in overweight or obese adults, drinking green tea did not significantly affect weight loss or maintenance of weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2961/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=see_link&amp;anchor=H33#H33\">",
"     \"Drug therapy of obesity\", section on 'Dietary supplements'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     OSTEOPOROSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Bisphosphonates in solid organ transplantation",
"    </span>",
"   </p>",
"   <p>",
"    Bisphosphonates are effective for prevention of bone loss after solid organ or stem cell transplant. There are few data to support the use of one bisphosphonate over another. In one trial, 84 adults undergoing liver or heart transplant were randomly assigned to zoledronic acid (single 5 mg infusion) or alendronate (70 mg weekly) initiated within 30 days of transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2961/abstract/6\">",
"     6",
"    </a>",
"    ]. Both groups were also compared with a reference group of concurrently transplanted patients who had T-scores &ge;-1.5 and who declined participation in the randomized trial. After 12 months, femoral neck and total hip bone mineral density did not change significantly from baseline in the zoledronic acid and alendronate groups. Lumbar spine bone mineral density increased from baseline (2.0 percent) in the zoledronic acid group and did not change in the alendronate group. In the reference group, bone mineral density declined at all sites. Thus, either oral or intravenous bisphosphonates can be administered. We favor intravenous zoledronic acid for patients at high risk for fracture (eg, osteoporosis at baseline, prior vertebral fragility fracture, T-scores below -1.5 prior to beginning glucocorticoids) and for those who find the weekly dosing schedule of alendronate too burdensome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29561?source=see_link&amp;anchor=H11#H11\">",
"     \"Osteoporosis after solid organ or stem cell transplantation\", section on 'Bisphosphonates'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Calcitonin for osteoporosis",
"    </span>",
"   </p>",
"   <p>",
"    The European Medicines Agency reviewed data provided by the companies who manufacture calcitonin-containing medications, post-marketing safety data, and randomized trials and reported that a higher proportion of patients treated with calcitonin-containing medications for long periods of time developed cancer (various types) than patients taking placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2961/abstract/7\">",
"     7",
"    </a>",
"    ]. The increases in cancer rates were small and ranged from 0.7 to 2.4 percent for oral and nasal calcitonin formulations, respectively. Because calcitonin is a weak osteoporosis drug, and there are more effective drugs to prevent bone loss and fracture, the European Medicines Agency concluded that the benefits of calcitonin do not outweigh the risks for the treatment of osteoporosis. We typically do not use calcitonin to treat osteoporosis, unless pain from an acute osteoporotic fracture is a problem. In this setting, calcitonin could be used in the short-term (until the pain has abated), and then the patient should be switched to an osteoporosis therapy that more effectively prevents subsequent fracture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43173?source=see_link&amp;anchor=H6#H6\">",
"     \"Calcitonin in the prevention and treatment of osteoporosis\", section on 'Concerns about the use of calcitonin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PITUITARY DISORDERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pasireotide for Cushing's disease",
"    </span>",
"   </p>",
"   <p>",
"    Pasireotide is a new somatostatin analog that blocks the release of ACTH from the pituitary. It has been approved in a number of countries for the treatment of hypercortisolism in patients with Cushing&rsquo;s disease (corticotropin (ACTH)-producing pituitary tumors) in whom pituitary surgery is contraindicated or unsuccessful [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2961/abstract/8\">",
"     8",
"    </a>",
"    ]. When administered at a dose of 600 to 900 mcg subcutaneously twice daily for six months, pasireotide therapy normalized 24-hour urine free cortisol in approximately 25 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2961/abstract/9\">",
"     9",
"    </a>",
"    ]; greater benefit was achieved when combined with cabergoline, or cabergoline plus ketoconazole therapy. Pasireotide was approved in the United States in December 2012 by the Food and Drug Administration [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2961/abstract/10\">",
"     10",
"    </a>",
"    ]. It is available in Europe and is expected to be available in the US in March 2013. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3081?source=see_link&amp;anchor=H458568732#H458568732\">",
"     \"Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)\", section on 'Pasireotide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     THYROID DISORDERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cabozantinib",
"    </span>",
"   </p>",
"   <p>",
"    In 2012, cabozantinib was approved by the US Food and Drug Administration for the treatment of progressive, metastatic medullary thyroid cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2961/abstract/11\">",
"     11",
"    </a>",
"    ]. Cabozantinib is an oral, small molecule&nbsp;tyrosine kinase inhibitor&nbsp;that targets VEGFRs 1 and 2, c-MET, and RET. In a randomized trial, 330 patients with progressive, metastatic, or unresectable locally advanced medullary thyroid cancer were randomly assigned to receive either cabozantinib or placebo once daily [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2961/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. A significant prolongation in progression free survival was observed for cabozantinib treatment compared with placebo. Partial responses were observed in 27 versus 0 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23288?source=see_link&amp;anchor=H652134#H652134\">",
"     \"Chemotherapy and immunotherapy for medullary thyroid cancer\", section on 'Cabozantinib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     OTHER ENDOCRINOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Mediterranean diet",
"    </span>",
"   </p>",
"   <p>",
"    A large randomized trial compared three diets in patients at high cardiovascular risk: a Mediterranean diet supplemented with olive oil, a Mediterranean diet supplemented with mixed nuts, and advice to reduce dietary fat [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2961/abstract/13\">",
"     13",
"    </a>",
"    ]. The trial was stopped early after a median follow-up of 4.8 years. For the primary composite cardiovascular endpoint of myocardial infarction, stroke, and cardiovascular death, event rates were similar for the Mediterranean diets supplemented with olive oil and mixed nuts, and lower than for the control diet (8.1 and 8.0 events per 1000 person-years respectively, versus 11.2 events per 1000 person-years; HR for both Mediterranean diets combined 0.71). Although this trial suggests possible substantial cardiovascular benefits from a Mediterranean diet, there was a surprisingly large reduction in events, a low total number of events (288), and the trial was stopped early for benefit. This raises concerns that the apparent benefits of a Mediterranean diet could have been overestimated, since this can be a problem in trials that are stopped early for benefit, particularly when there are also relatively few events [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2961/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=see_link&amp;anchor=H20#H20\">",
"     \"Lipid lowering with diet or dietary supplements\", section on 'Mediterranean diet'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2961/abstract/1\">",
"      Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet 2012; 380:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2961/abstract/2\">",
"      Nelson HD, Walker M, Zakher B, Mitchell J. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. Preventive Services Task Force recommendations. Ann Intern Med 2012; 157:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2961/abstract/3\">",
"      Moyer VA, U.S. Preventive Services Task Force. Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013; 158:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2961/abstract/4\">",
"      Rossouw JE, Manson JE, Kaunitz AM, Anderson GL. Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy. Obstet Gynecol 2013; 121:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2961/abstract/5\">",
"      Jurgens TM, Whelan AM, Killian L, et al. Green tea for weight loss and weight maintenance in overweight or obese adults. Cochrane Database Syst Rev 2012; 12:CD008650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2961/abstract/6\">",
"      Shane E, Cohen A, Stein EM, et al. Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation. J Clin Endocrinol Metab 2012; 97:4481.",
"     </a>",
"    </li>",
"    <li>",
"     European Medicines Agency recommends limiting long-term use of calcitonin medicines file://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2012/07/human_pha_detail_000065.jsp&amp;mid=WC0b01ac058001d126 (Accessed on October 17, 2012).",
"    </li>",
"    <li>",
"     European Medicines Agency. Summary of product characteristics: Signifor 0.3 mg solution for injection. file://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002052/WC500128056.pdf (Accessed on December 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2961/abstract/9\">",
"      Colao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med 2012; 366:914.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Press Release: FDA approves Signifor, a new orphan drug for Cushing&rsquo;s disease (December 2012) file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332351.htm (Accessed on January 16, 2013).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. FDA approves Cometriq to treat rare type of thyroid cancer. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm330143.htm (Accessed on December 03, 2012).",
"    </li>",
"    <li>",
"     Schoffski P, Elisei R, Muller S, et al. An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. J Clin Oncol 2012; 30 (suppl):5508. file://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5508 (Accessed on January 25, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2961/abstract/13\">",
"      Estruch R, Ros E, Salas-Salvad&oacute; J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. N Engl J Med 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2961/abstract/14\">",
"      Montori VM, Devereaux PJ, Adhikari NK, et al. Randomized trials stopped early for benefit: a systematic review. JAMA 2005; 294:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2961/abstract/15\">",
"      Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 2010; 303:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2961/abstract/16\">",
"      Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol 2011; 64:1283.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8354 Version 2375.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"footerNav\">",
"   <ul>",
"    <li>",
"     <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Wolters Kluwer Health",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Facts &amp; Comparisons&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"      Medi-Span&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Order Sets",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Medical",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Pharmacy OneSource&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"      Medicom",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Lexicomp",
"     </a>",
"    </li>",
"    <li class=\"last\">",
"     <a href=\"/home/privacy-policy\">",
"      Privacy Policy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <div id=\"footerLogo\">",
"   <a href=\"./toc\">",
"    Wolters Kluwer Health | UpToDate",
"   </a>",
"  </div>",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"sfInfo\">",
"    <a href=\"/home/terms-use\">",
"     Terms of Use",
"    </a>",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     UpToDate Marketing Professional",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-125.39.66.150-11767895B5-14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_57_2961=[""].join("\n");
var outline_f2_57_2961=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      DIABETES MELITUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Screening for diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FEMALE REPRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Long-term use of postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      OBESITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Green tea and management of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      OSTEOPOROSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Bisphosphonates in solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Calcitonin for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PITUITARY DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pasireotide for Cushing's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      THYROID DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cabozantinib",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      OTHER ENDOCRINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Mediterranean diet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43173?source=related_link\">",
"      Calcitonin in the prevention and treatment of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23288?source=related_link\">",
"      Chemotherapy and immunotherapy for medullary thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=related_link\">",
"      Drug therapy of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=related_link\">",
"      Lipid lowering with diet or dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3081?source=related_link\">",
"      Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29561?source=related_link\">",
"      Osteoporosis after solid organ or stem cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2312?source=related_link\">",
"      Screening for diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_57_2962="Reactive arthritis of knee";
var content_f2_57_2962=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F67863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F67863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Asymmetical arthritis of the knees",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 322px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Asymmetrical swelling due to reactive arthritis is apparent in this photograph. The patellar borders are effaced and there is suprapatellar fullness of the left knee.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Filip de Keyser.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_57_2962=[""].join("\n");
var outline_f2_57_2962=null;
var title_f2_57_2963="Proparacaine: Drug information";
var content_f2_57_2963=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Proparacaine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/20/2372?source=see_link\">",
"    see \"Proparacaine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/19/36146?source=see_link\">",
"    see \"Proparacaine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F214470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alcaine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F214471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alcaine&reg;;",
"     </li>",
"     <li>",
"      Diocaine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F214494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Local Anesthetic, Ophthalmic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F214473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ophthalmic surgery:",
"     </b>",
"     Ophthalmic: Instill 1 drop of 0.5% solution in eye every 5-10 minutes for 5-7 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tonometry, gonioscopy, suture removal:",
"     </b>",
"     Ophthalmic: Instill 1-2 drops of 0.5% solution in eye just prior to procedure",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F214485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/19/36146?source=see_link\">",
"      see \"Proparacaine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children: Refer to adult dosing",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F214474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F214458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as hydrochloride [drops]: 0.5% (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alcaine&reg;: 0.5% (15 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F214445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F214460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not use if discolored; protect eye from irritating chemicals, foreign bodies, and blink reflex; use eye patch if necessary",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F214459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anesthesia for tonometry, gonioscopy; suture removal from cornea; removal of corneal foreign body; cataract extraction, glaucoma surgery; short operative procedure involving the cornea and conjunctiva",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F214492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Local: Burning, stinging, redness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic contact dermatitis, arrhythmia, blurred vision, CNS depression, conjunctival congestion and hemorrhage, corneal opacification, diaphoresis increased, epithelium, erosion of the corneal iritis, irritation, keratitis, lacrimation, sensitization",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F214463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to proparacaine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F214449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For topical ophthalmic use only; prolonged use not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F214453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F214455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14079706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F14079707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F214464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Alcaine Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (15 mL): $46.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Proparacaine HCl Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (15 mL): $17.45",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alcaine (AE, AU, BE, BF, BH, BJ, CH, CI, CL, CY, EG, ET, GH, GM, GN, GR, HK, IL, IQ, IR, JO, KE, KP, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, NO, OM, PH, PK, PL, QA, RU, SA, SC, SD, SL, SN, SY, TN, TR, TW, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Anestalcon (AR, BR, CN);",
"     </li>",
"     <li>",
"      Keracaine (FR, LU);",
"     </li>",
"     <li>",
"      Minims Proxymetacaine Hydrochloride (GB);",
"     </li>",
"     <li>",
"      Miraxil (CO);",
"     </li>",
"     <li>",
"      Ophthaine (GB, IE);",
"     </li>",
"     <li>",
"      Opthetic (NZ);",
"     </li>",
"     <li>",
"      Poen-Caina (UY);",
"     </li>",
"     <li>",
"      Proparakain-POS (DE);",
"     </li>",
"     <li>",
"      Visonest (BR);",
"     </li>",
"     <li>",
"      Visuanestetico (IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F214448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevents initiation and transmission of impulse at the nerve cell membrane by decreasing ion permeability through stabilizing",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F214462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: &sim;20 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 15-20 minutes",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2007, 64(16):1711-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/57/2963/abstract-text/17687059/pubmed\" id=\"17687059\" target=\"_blank\">",
"        17687059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9824 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-27.109.116.13-B2EFA6BE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_57_2963=[""].join("\n");
var outline_f2_57_2963=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214470\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214471\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214494\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214473\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214485\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214474\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214458\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214445\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214460\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214459\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214492\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214463\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214449\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299950\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214453\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214455\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14079706\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14079707\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214464\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038785\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214448\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214462\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9824\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9824|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/20/2372?source=related_link\">",
"      Proparacaine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/19/36146?source=related_link\">",
"      Proparacaine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_57_2964="Pyoderma gangrenosum - close view of ulcer";
var content_f2_57_2964=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52291&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52291&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pyoderma gangrenosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This purulent ulcer with a ragged and violaceous border is consistent with pyoderma gangrenosum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_57_2964=[""].join("\n");
var outline_f2_57_2964=null;
var title_f2_57_2965="Aspirin and extended-release dipyridamole: Patient drug information";
var content_f2_57_2965=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Aspirin and extended-release dipyridamole: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19271?source=see_link\">",
"     see \"Aspirin and extended-release dipyridamole: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F161522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aggrenox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F161523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aggrenox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop strokes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to aspirin, dipyridamole, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, bleeding problems, nose polyps, or rhinitis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 24 weeks pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697889",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain or heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ringing in ears.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11014 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.102.30.19-B30E4C65A7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_57_2965=[""].join("\n");
var outline_f2_57_2965=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161522\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161523\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018494\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018496\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018495\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018500\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018501\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018503\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018498\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018499\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018504\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018505\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19271?source=related_link\">",
"      Aspirin and extended-release dipyridamole: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_57_2966="LeFort fractures of the midface";
var content_f2_57_2966=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55687&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55687&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    LeFort fractures of the midface",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 398px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    LeFort fractures are those of the midface that involve the maxillary dentoalveolar segment. The mechanism and location of impact usually determine the type of fracture sustained. Fractures tend to occur in certain patterns of the midface and are traditionally classified by the highest level of fracture. Most LeFort fractures are not \"pure\" and can have comminution, additional levels or lines of fracture, and other associated facial fractures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ochs MW. Bony Oral-Maxillofacial Injuries. In: The Trauma Manual: Trauma and Acute Care Surgery, 3rd edition, Peitzman AB, Rhodes M, Schwab CW, et al. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_57_2966=[""].join("\n");
var outline_f2_57_2966=null;
var title_f2_57_2967="Hepatocellular carcinoma - low power";
var content_f2_57_2967=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hepatocellular carcinoma (low power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal appearance of liver plates is replaced by thicker bands of malignant hepatocytes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_57_2967=[""].join("\n");
var outline_f2_57_2967=null;
var title_f2_57_2968="New daily persistent headache";
var content_f2_57_2968=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   New daily persistent headache",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/57/2968/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/57/2968/contributors\">",
"     Ivan Garza, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/57/2968/contributors\">",
"     Todd J Schwedt, MD, MSCI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/57/2968/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/57/2968/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/57/2968/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/57/2968/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/57/2968/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic daily headache is a descriptive term that encompasses several different specific headache diagnoses characterized by frequent headaches. Chronic daily headache types with individual headaches of long duration (ie, four hours or more) include chronic migraine (",
"    <a class=\"graphic graphic_table graphicRef56064 \" href=\"UTD.htm?33/14/34027\">",
"     table 1",
"    </a>",
"    ), chronic tension-type headache (",
"    <a class=\"graphic graphic_table graphicRef68892 \" href=\"UTD.htm?38/22/39275\">",
"     table 2",
"    </a>",
"    ), medication overuse headache (",
"    <a class=\"graphic graphic_table graphicRef71798 \" href=\"UTD.htm?8/35/8763\">",
"     table 3",
"    </a>",
"    ), hemicrania continua (",
"    <a class=\"graphic graphic_table graphicRef62652 \" href=\"UTD.htm?29/56/30603\">",
"     table 4",
"    </a>",
"    ), and new daily persistent headache (",
"    <a class=\"graphic graphic_table graphicRef76010 \" href=\"UTD.htm?34/48/35595\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37830?source=see_link\">",
"     \"Overview of chronic daily headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unique to the syndrome of new daily persistent headache (NDPH) is the fact that the headache begins one day and typically does not remit. Many patients can pinpoint the exact date their headache started. New daily persistent headache was first described in 1986 as a benign form of chronic daily headache that improved over time without therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/1\">",
"     1",
"    </a>",
"    ]. However, in other studies and in practice, NDPH can endure for many years or even decades and be completely refractory to treatment.",
"   </p>",
"   <p>",
"    This topic will discuss NDPH. Other types of chronic daily headache are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37830?source=see_link\">",
"     \"Overview of chronic daily headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of NDPH is poorly understood. Some but not all reports suggest that the onset of NDPH can be triggered by certain events. In a series of 56 patients, NDPH onset occurred at the time of an infection or flu-like illness, extracranial surgery, or a stressful life event in 30, 12, and 12 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/2\">",
"     2",
"    </a>",
"    ]. Among 40 children with NDPH, headache onset was linked with infection, minor head trauma, idiopathic intracranial hypertension, and surgery in 43, 40, 10, and 10 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/3\">",
"     3",
"    </a>",
"    ]. However, in a series of 30 adolescent and adult patients from Japan, no precipitating factors were elucidated in 80 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The observation that headache onset can occur in relation to infection or flu-like illness has triggered interest in a possible microbial etiology. However, the potential role of viral or other infection in NDPH pathogenesis (if any) remains to be determined.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case-control study found evidence of active Epstein-Barr virus (EBV) infection in 27 of 32 patients (85 percent) with NDPH compared with 8 of 32 controls (25 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/5\">",
"       5",
"      </a>",
"      ]. The authors concluded that EBV reactivation might have a pathogenic role in NDPH.",
"     </li>",
"     <li>",
"      A series of 56 patients found evidence of past EBV exposure in seven (13 percent), but no active infection [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective analysis of 18 NDPH cases, there was evidence of recent infection with herpes simplex virus (HSV) in six patients, and cytomegalovirus (CMV) in two, but no evidence of EBV [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/6\">",
"       6",
"      </a>",
"      ]. Of note, the positive cases for HSV or CMV had been seen within 60 days of headache onset.",
"     </li>",
"     <li>",
"      In an uncontrolled study of 108 cases of new daily headache, clinical or laboratory evidence suggestive of extracranial or systemic infections was detected in nearly all patients [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/7\">",
"       7",
"      </a>",
"      ]. The mean headache duration was approximately 14 days, which is too short to meet current ICHD-2 criteria for NDPH. However, the study does alert the clinician that a new daily headache can be secondary to intracranial or extracranial infection and that further investigations may be warranted when appropriate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    How an infection may cause NDPH is unknown. An activated autoimmune response that may lead to persistent neurogenic inflammation has been hypothesized [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/8\">",
"     8",
"    </a>",
"    ], but remains unproven. In a study that evaluated 20 patients with NDPH and a control population of 18 patients (16 with chronic migraine and 2 with post-traumatic headache), elevated cerebrospinal fluid levels of tumor necrosis factor alpha, a proinflammatory cytokine, were found in 95 percent of patients with NDPH and 100 percent of the control patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/9\">",
"     9",
"    </a>",
"    ]. No headache-free controls were investigated. Whether this cytokine plays a causal role in NDPH or other headaches remains unclear.",
"   </p>",
"   <p>",
"    Only a minority of patients with NDPH has a history of prior headaches [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. Some individuals have a family history of headache, but there is no good evidence that NDPH is inherited.",
"   </p>",
"   <p>",
"    To summarize, the link between NDPH and potential risk factors or inciting events such as infection, trauma, or surgery is not firmly established. These factors probably do not cause the headache, but rather may incite an underlying predisposition to headaches [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/3\">",
"     3",
"    </a>",
"    ]. An unanswered question is why the headache persists so long, even after the inciting factor has resolved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;When compared with other primary headache disorders, NDPH appears to be rare, but it has been described in multiple ethnic groups, including white, black, Hispanic and Asian [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. However, the incidence and prevalence of NDPH in the general population are unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies from headache clinics suggest that NDPH is more frequent in children than in adults, and affects women more often than men.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 2232 new headache cases, 265 patients had \"chronic\" headache. Of these, NDPH was diagnosed in 18 (7 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/6\">",
"       6",
"      </a>",
"      ]. The definition of \"chronic\" was not provided.",
"     </li>",
"     <li>",
"      In a study of patients with chronic daily headache that included both adolescents (n = 170) and adults (n = 638), the frequency of NDPH was 21 and 11 percent respectively, and the difference was statistically significant [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a report from a tertiary US headache clinic of 175 children with chronic daily headache, the frequency of NDPH was 23 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another US tertiary headache clinic study of 187 children and adolescents with chronic daily headache, the frequency of NDPH was 31 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The female-to-male ratio of NDPH has ranged from 1.3 to 2.5 [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/1,2,4\">",
"       1,2,4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The age of onset for NDPH extends from the early teens to &gt;70 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. In a series from Japan of 30 patients with NDPH, the mean age of onset was 35 years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/4\">",
"     4",
"    </a>",
"    ]. In another report, the peak age of onset was earlier for women (the second and third decade) than for men (the fifth decade) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/2\">",
"     2",
"    </a>",
"    ]. Similarly, the first report describing NDPH found an earlier age of onset for women (16 to 35 years) than for men (26 to 45 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unique to NDPH is the fact that the headache begins one day and typically does not remit. Up to 80 percent of patients with NDPH can pinpoint the exact date their headache started [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/2\">",
"     2",
"    </a>",
"    ]. Some patients awaken from sleep with the headache, while others note the onset while awake. The pain is typically bilateral, pressing or tightening in quality, and of mild to moderate intensity. There may be photophobia, phonophobia, or mild nausea [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In practice, however, considerable variability is seen in the clinical features of NDPH:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The duration of the daily headache can range from 1.5 to 24 hours, but most patients (approximately 80 percent) experience continuous headache pain throughout the day with no pain-free time [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/2,4\">",
"       2,4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The baseline average pain intensity associated with NDPH is typically moderate, although a significant proportion of patients experience severe pain all the time [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The headache of NDPH is bilateral in 64 to 86 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/1,2,4\">",
"       1,2,4",
"      </a>",
"      ]. The pain can be holocranial or localize to any head region, including occipital-nuchal, temporal, and retroorbital locations.",
"     </li>",
"     <li>",
"      The quality of the head pain is most often throbbing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pressure-like. Migrainous features are common. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Headache phenotype'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The course may be either self-limited or refractory. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Prognosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Headache phenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;The quality of the head pain with NDPH is most often throbbing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pressure-like. In many cases, the phenotype resembles migraine or, less often, tension-type headache [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/1,2,4,6,11\">",
"     1,2,4,6,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 56 patients with NDPH from a US referral center, the following observations were noted [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/2\">",
"       2",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Headaches were throbbing in 55 percent and pressure-like in 54 percent; other common descriptions include stabbing, aching, dullness, tightness, burning, and searing",
"     </li>",
"     <li>",
"      Associated \"migrainous\" symptoms were frequent and included nausea (68 percent), photophobia (66 percent), phonophobia (61 percent), lightheadedness (55 percent),",
"      <span class=\"nowrap\">",
"       sore/stiff",
"      </span>",
"      neck (50 percent), blurred vision (43 percent), vomiting (23 percent), and vertigo (11 percent)",
"     </li>",
"     <li>",
"      Headaches were aggravated by stress (40 percent), physical exertion (32 percent), and bright light (29 percent)",
"     </li>",
"     <li>",
"      Headaches were relieved by lying down (66 percent), being in a dark room (48 percent), by massage (23 percent), and by sleep (9 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 53 children and adolescents at a US headache clinic diagnosed with NDPH but not overusing medication, most headache days (average 18.5 per month) met criteria for migraine [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In a series of 30 patients from Japan, tension-type headache pain, characterized by pressing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tightening, was frequent (73 percent), while the remaining patients had pulsating (10 percent) or both",
"      <span class=\"nowrap\">",
"       pressing/tightening",
"      </span>",
"      and pulsating pain (17 percent). Associated symptoms included mild nausea (33 percent) and photophobia (3 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/4\">",
"       4",
"      </a>",
"      ]. The predominance of tension-type headache pain in this series was probably due to the use of current diagnostic criteria that exclude patients with a migraine-like phenotype. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnostic criteria'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neurologic examination is typically normal in NDPH. Greater occipital nerve trigger point tenderness and evidence of cervical facet inflammation on neck extension and rotation maneuvers may be seen in some [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/2\">",
"     2",
"    </a>",
"    ]. The significance of this finding is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of NDPH is based upon the clinical features, fulfillment of diagnostic criteria (",
"    <a class=\"graphic graphic_table graphicRef76010 \" href=\"UTD.htm?34/48/35595\">",
"     table 5",
"    </a>",
"    ), and exclusion of secondary causes of headache. However, current diagnostic criteria are problematic because they tend to exclude patients with predominant migrainous features, even though migrainous features are common in NDPH [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Diagnostic criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Secondary headache disorders must be ruled out before making a diagnosis of NDPH [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/12\">",
"     12",
"    </a>",
"    ], even in the presence of a normal neurologic examination. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Evaluation'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H10\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Classification of Headache Disorders (ICHD-2) describes NDPH as a daily headache that is unremitting from onset or very soon after onset (within three days at most). However, these criteria are problematic because they emphasize tension-type headache features while excluding patients with predominant migrainous features.",
"   </p>",
"   <p>",
"    The following are the ICHD-2 diagnostic criteria for NDPH [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Headache for more than three months fulfilling criteria B through D",
"     </li>",
"     <li>",
"      B. Headache is daily and unremitting from onset or from less than three days from onset",
"     </li>",
"     <li>",
"      C. At least two of the following pain characteristics:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Bilateral location",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Pressing/tightening",
"      </span>",
"      (nonpulsating) quality",
"     </li>",
"     <li>",
"      Mild or moderate intensity",
"     </li>",
"     <li>",
"      Not aggravated by routine physical activity such as walking or climbing stairs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      D. Both of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      No more than one of photophobia, phonophobia or mild nausea",
"     </li>",
"     <li>",
"      Neither moderate or severe nausea nor vomiting",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      E. Not attributed to another disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contradistinction to what the ICHD-2 criteria require, patients with NDPH can present with primarily migrainous symptoms, such as unilateral headache, photophobia, phonophobia, throbbing headache, nausea, and vomiting. Thus, the ICHD-2 criteria may not reflect what is seen in clinical practice and may need to be modified. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Headache phenotype'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Many experts make the diagnosis of NDPH despite the presence of migrainous features (ie, they do not apply criterion C or D above) and thus are already using a modified version of the ICHD-2 criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/11,13-15\">",
"     11,13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features of patients with a phenotype of NDPH are generally similar regardless of whether or not they fulfill the ICHD-2 criteria. This point is illustrated by a study that used modified criteria (allowing prominent migraine features) for the diagnosis of NDPH [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/15\">",
"     15",
"    </a>",
"    ]. Altogether, 71 patients with a phenotype of NDPH were included. Of these, 31 (44 percent) met ICHD-2 criteria, and 40 (56 percent), designated NDPH with migraine features, did not.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no significant difference between these two patient groups in headache characteristics, including pain severity, autonomic symptoms, prevalence of allodynia, medication overuse, responsiveness to triptans, and prognosis.",
"     </li>",
"     <li>",
"      A few demographic differences emerged. Compared with patients who met ICHD-2 criteria, patients who had NDPH with migraine features were more likely to be women (83 versus 58 percent), more likely to have depression (48 versus 19 percent), and less likely to recall the specific day or month of headache onset (73 versus 97 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given these data, particularly the exclusion of nearly 60 percent of patients and lack of value for choosing treatment with use of the ICHD-2 criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/14\">",
"     14",
"    </a>",
"    ], we suggest use of the modified criteria for the diagnosis of NDPH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;New headache onset in the absence of a headache history always warrants attention. Therefore, the initial evaluation of acute NDPH must exclude secondary causes of headache. We recommend neuroimaging for patients with acute (within the first few weeks from onset) headache suspicious for NDPH. Where available, we suggest brain MRI with gadolinium as the initial imaging study. Head CT with contrast is an alternative for those who cannot have MRI because of intolerance, contraindications, or availability.",
"   </p>",
"   <p>",
"    For select patients with recent onset of headache suspicious for NDPH, additional studies may be warranted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vascular imaging with MR venography is indicated in addition to brain MRI if there is suspicion for cerebral venous sinus thrombosis. A hypercoagulable state or signs of raised intracranial pressure (papilledema) lower the threshold for obtaining MR venography.",
"     </li>",
"     <li>",
"      Lumbar puncture is indicated if there is suspicion for central nervous system infection or idiopathic intracranial hypertension (pseudotumor cerebri). Meningismus or fever lowers the threshold for a lumbar puncture.",
"     </li>",
"     <li>",
"      Giant cell arteritis should be ruled out in patients over 50 years old [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of secondary and primary causes of headache may mimic NDPH. Particularly important entities in the differential are cerebral venous sinus thrombosis, headache due to cerebrospinal fluid leak , idiopathic intracranial hypertension (pseudotumor cerebri) and giant cell arteritis.",
"   </p>",
"   <p>",
"    Other secondary causes that can mimic NDPH include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Brain tumor",
"     </li>",
"     <li>",
"      Chronic meningitis",
"     </li>",
"     <li>",
"      Chronic subdural hematoma",
"     </li>",
"     <li>",
"      Dissection of carotid or vertebral artery",
"     </li>",
"     <li>",
"      Dural arteriovenous fistula",
"     </li>",
"     <li>",
"      Leptomeningeal metastasis",
"     </li>",
"     <li>",
"      Postmeningitis headache",
"     </li>",
"     <li>",
"      Posttraumatic headache",
"     </li>",
"     <li>",
"      Sphenoid sinusitis",
"     </li>",
"     <li>",
"      Subarachnoid hemorrhage",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cerebral venous sinus thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to headache, most patients with symptomatic cerebral venous sinus thrombosis will present with other manifestations, such as papilledema, seizures, focal deficits, encephalopathy, cranial nerve palsies, bilateral cortical signs,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cerebellar signs [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/17\">",
"     17",
"    </a>",
"    ]. However, these may be absent even in the presence of thrombus [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/16\">",
"     16",
"    </a>",
"    ], and a new daily headache may be the only symptom. In this setting, cerebral venous sinus thrombosis can be misdiagnosed as idiopathic intracranial hypertensions or NDPH [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/17\">",
"     17",
"    </a>",
"    ]. Brain MRI in combination with MR venography can help to demonstrate the thrombus and the occluded dural sinus or vein in a noninvasive manner. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=see_link\">",
"     \"Etiology, clinical features, and diagnosis of cerebral venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Spontaneous cerebrospinal fluid leak headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is crucial to consider headache secondary to spontaneous cerebrospinal fluid (CSF) leaks in the differential diagnosis of NDPH since the syndrome can usually be treated successfully with appropriate interventions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/20/330?source=see_link\">",
"     \"Pathophysiology, clinical features, and diagnosis of spontaneous low cerebrospinal fluid pressure headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13126?source=see_link\">",
"     \"Treatment and prognosis of spontaneous low cerebrospinal fluid pressure headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, some patients who met NDPH criteria in one report were later found to have a CSF leak [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/2\">",
"     2",
"    </a>",
"    ]. Treatment of the CSF leak led to complete headache resolution.",
"   </p>",
"   <p>",
"    In CSF leaks, headaches typically resolve or are significantly alleviated while lying down but recur while upright. Brain MRI usually shows diffuse pachymeningeal gadolinium enhancement",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    brain descent, and opening CSF pressures on lumbar puncture are typically low (&le;70 mmH20). However, the orthostatic component and other key clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neuroimaging features are not always present, making CSF leaks hard to diagnose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/20/330?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathophysiology, clinical features, and diagnosis of spontaneous low cerebrospinal fluid pressure headache\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Idiopathic intracranial hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic intracranial hypertension (IIH, also called pseudotumor cerebri) typically presents with headache upon waking, and gets better as the day goes on. It is generally worse with recumbency. In addition, visual obscurations are frequently reported. The diagnosis of IIH should be considered particularly in obese women, who account for most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17417?source=see_link\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When papilledema is present, the diagnosis of IIH is straightforward [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/19\">",
"     19",
"    </a>",
"    ]. A neuroimaging study is required to exclude other causes of elevated intracranial pressure. Brain MRI with and without contrast and postcontrast MR venography is the imaging study of choice. Lumbar puncture should follow MRI unless a source of elevated intracranial pressure is clearly delineated. An opening pressure greater than 250 mmH2O taken with the patient lying on the side with legs extended confirms elevated intracranial pressure. Pressures between 200 and 250 mmH2O are considered equivocal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17417?source=see_link&amp;anchor=H15#H15\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Giant cell arteritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of giant cell (temporal) arteritis should be ruled out in patients over 50 years old who have any combination of headache, abrupt onset of visual disturbances, symptoms of polymyalgia rheumatica, unexplained fever or anemia, elevated erythrocyte sedimentation rate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serum C-reactive protein. Temporal artery biopsy is the gold standard for confirming the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34599?source=see_link\">",
"     \"Diagnosis of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Primary headache disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary headache disorders may mimic NDPH. Although chronic tension-type headache and NDPH have many similarities, NDPH is unique in that headache is daily and unremitting from, or almost from, the moment of onset, typically in individuals without a prior headache history. A clear recall of such an onset is necessary for the diagnosis of NDPH [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/12\">",
"     12",
"    </a>",
"    ]. If strictly unilateral, hemicrania continua may be a more likely diagnosis than NDPH. A trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    can be both diagnostic and therapeutic in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43942?source=see_link\">",
"     \"Hemicrania continua\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The combination of daily headaches in the setting of medication overuse may create diagnostic uncertainty. In this situation, one needs to ask about the temporal relationship between headache onset and the development of daily headache.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In NDPH, the headache is daily and unremitting from onset in a patient who is not yet overusing analgesics. Unlike medication overuse headache, the overuse in NDPH begins after the onset of daily headache.",
"     </li>",
"     <li>",
"      In contrast, some patients with ongoing episodic migraine or tension-type headache progressively consume analgesics in an attempt to fight the gradually increasing headache frequency [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/16\">",
"       16",
"      </a>",
"      ]. The medication overuse begins before the onset of daily headache.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nevertheless, many NDPH sufferers are overusing analgesics by the time they are seen in clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;New daily persistent headache appears to have two subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A self-limited form (nonpersisting), which typically resolves without therapy within several months",
"     </li>",
"     <li>",
"      A refractory form (persisting) that is resistant to aggressive treatment regimens",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Very likely, the refractory form is the one seen in the clinician's office. Self-limited forms may not reach medical attention.",
"   </p>",
"   <p>",
"    The original report describing NDPH with 45 patients (19 male, 26 female) found that, at two years from onset, 16 men (84 percent) and 19 women (73 percent) were headache-free without treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/1\">",
"     1",
"    </a>",
"    ]. In a later series of 18 cases, the number of patients pain-free at two years after headache onset was 12 (66 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in other studies and in practice, NDPH can endure for many years or even decades and be completely refractory to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a US series of 56 patients, all patients at study entry had NDPH for at least six months, many had headache for more than five years, and a few had headache for more than 10 years [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series from Japan, the duration of NDPH at study entry ranged from three months to 27 years (mean approximately 3.3 years) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The true long-term prognosis of refractory NDPH is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the phenotype of NDPH often resembles primary chronic tension-type headache or a chronic migraine. Although evidence is lacking, it is intuitive to treat NDPH based on the phenotype. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Headache phenotype'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Thus, our suggested approach is to first classify the phenotype of NDPH as most similar to either migraine or chronic tension-type headache, and then treat with appropriate preventive headache therapy accordingly [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link\">",
"     \"Preventive treatment of migraine in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1433?source=see_link\">",
"     \"Tension-type headache in adults: Preventive treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18490?source=see_link\">",
"     \"Management of migraine headache in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34744?source=see_link\">",
"     \"Tension-type headache in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NDPH can continue for years or even decades after onset and can be very disabling. Even with aggressive treatment, including medications from multiple classes of abortives and prophylactics, many patients do not improve [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/16\">",
"     16",
"    </a>",
"    ]. Many headache specialists consider NDPH to be the most treatment refractory of all headache disorders.",
"   </p>",
"   <p>",
"    Data regarding the effectiveness of specific treatments for primary NDPH are limited to small series and case reports.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, 30 patients with NDPH were treated for five years, beginning with muscle relaxants (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/35/12855?source=see_link\">",
"       tizanidine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"       baclofen",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/4\">",
"       4",
"      </a>",
"      ]. Patients who did not respond were subsequently treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      , serotonin specific reuptake inhibitors (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"       fluvoxamine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      ),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      valproic acid. By self-assessment, the outcome was considered very effective, moderately effective, mildly effective, and not effective in 27, 3, 20, and 50 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some headache experts have reported successful therapy of NDPH with a variety of agents, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"       nortriptyline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/16,19,20\">",
"       16,19,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other authors have anecdotally seen benefit using nonsteroidal antiinflammatory drugs combined with muscle relaxants and neck physical therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some reports suggest the response rate to pharmacologic treatment is better early in the course of NDPH (eg, during the first year) compared with late (eg, at 10 to 20 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/16\">",
"     16",
"    </a>",
"    ]. However, this relationship has not been demonstrated in all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Analgesic overuse should be stopped if concurrent with NDPH, even though available evidence suggests that medication withdrawal typically does not help relieve the pain in NDPH [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2968/abstract/16\">",
"     16",
"    </a>",
"    ]. This contrasts with the improvement that often occurs with drug withdrawal in patients who have background migraine and medication overuse headache. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/48/17161?source=see_link\">",
"     \"Medication overuse headache: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      New daily persistent headache is a primary headache disorder in which headache begins one day and does not remit, usually in an individual without a headache history. The pathophysiology is poorly understood. Some but not all reports suggest that the onset of NDPH can be triggered by certain events, such as infection. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence and prevalence of NDPH in the general population are unknown, but NDPH appears to be rare. Available evidence suggests that NDPH is more frequent in children than in adults, and affects women more often than men. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A characteristic feature of NDPH is that the headache starts rather abruptly and is daily and unremitting from, or almost from, the moment of onset, typically in individuals without a prior headache history. Considerable variability is seen in the clinical features. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of NDPH is clinical (",
"      <a class=\"graphic graphic_table graphicRef76010 \" href=\"UTD.htm?34/48/35595\">",
"       table 5",
"      </a>",
"      ) and requires ruling out secondary causes of headache, even in the presence of a normal neurologic examination. While current diagnostic criteria exclude patients with predominant migrainous features, many headache experts contend that the diagnosis of NDPH can be made regardless of the presence of migrainous features. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with recent onset of suspected NDPH, we recommend neuroimaging upon presentation. For select patients, additional studies may be warranted. A lumbar puncture is indicated if clinical features suggest a possible central nervous system infection or idiopathic intracranial hypertension. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of NDPH includes a number of secondary and primary causes of headache. It is particularly important to consider cerebral venous sinus thrombosis, headache secondary to spontaneous cerebrospinal fluid leaks, idiopathic intracranial hypertension (pseudotumor cerebri), and giant cell arteritis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      New daily persistent headache may take either of two subtypes: a self-limited one, or a persistent form which can last years or decades and is challenging to treat. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with primary NDPH, we suggest first classifying the phenotype of NDPH as most similar to either migraine or tension-type headache, and then treating with appropriate preventive headache therapy accordingly (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2968/abstract/1\">",
"      Vanast, WJ. New daily persistent headaches: definition of a benign syndrome. Headache 1986; 26:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2968/abstract/2\">",
"      Li D, Rozen TD. The clinical characteristics of new daily persistent headache. Cephalalgia 2002; 22:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2968/abstract/3\">",
"      Mack KJ. What incites new daily persistent headache in children? Pediatr Neurol 2004; 31:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2968/abstract/4\">",
"      Takase Y, Nakano M, Tatsumi C, Matsuyama T. Clinical features, effectiveness of drug-based treatment, and prognosis of new daily persistent headache (NDPH): 30 cases in Japan. Cephalalgia 2004; 24:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2968/abstract/5\">",
"      Diaz-Mitoma F, Vanast WJ, Tyrrell DL. Increased frequency of Epstein-Barr virus excretion in patients with new daily persistent headaches. Lancet 1987; 1:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2968/abstract/6\">",
"      Meineri P, Torre E, Rota E, Grasso E. New daily persistent headache: clinical and serological characteristics in a retrospective study. Neurol Sci 2004; 25 Suppl 3:S281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2968/abstract/7\">",
"      Santoni JR, Santoni-Williams CJ. Headache and painful lymphadenopathy in extracranial or systemic infection: etiology of new daily persistent headaches. Intern Med 1993; 32:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2968/abstract/8\">",
"      Evans RW, Rozen TD. Etiology and treatment of new daily persistent headache. Headache 2001; 41:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2968/abstract/9\">",
"      Rozen T, Swidan SZ. Elevation of CSF tumor necrosis factor alpha levels in new daily persistent headache and treatment refractory chronic migraine. Headache 2007; 47:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2968/abstract/10\">",
"      Bigal ME, Lipton RB, Tepper SJ, et al. Primary chronic daily headache and its subtypes in adolescents and adults. Neurology 2004; 63:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2968/abstract/11\">",
"      Kung E, Tepper SJ, Rapoport AM, et al. New daily persistent headache in the paediatric population. Cephalalgia 2009; 29:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2968/abstract/12\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     Rozen TD. New Daily Persistent Headache. In: Chronic Daily Headache for Clinicians, Goadsby PJ, Dodick DW (Eds), BC Decker, Hamilton, Ontario 2005. p.209.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2968/abstract/14\">",
"      Young WB, Swanson JW. New daily-persistent headache: The switched-on headache. Neurology 2010; 74:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2968/abstract/15\">",
"      Robbins MS, Grosberg BM, Napchan U, et al. Clinical and prognostic subforms of new daily-persistent headache. Neurology 2010; 74:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2968/abstract/16\">",
"      Rozen TD. New daily persistent headache. Curr Pain Headache Rep 2003; 7:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2968/abstract/17\">",
"      Evans RW. New daily persistent headache. Curr Pain Headache Rep 2003; 7:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2968/abstract/18\">",
"      Garza I. Images from headache: a \"noisy\" headache: dural arteriovenous fistula resembling new daily persistent headache. Headache 2008; 48:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2968/abstract/19\">",
"      Goadsby PJ, Boes C. New daily persistent headache. J Neurol Neurosurg Psychiatry 2002; 72 Suppl 2:ii6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2968/abstract/20\">",
"      Mack KJ. New daily persistent headache in children and adults. Curr Pain Headache Rep 2009; 13:47.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3343 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-188.40.116.55-6D8648E745-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_57_2968=[""].join("\n");
var outline_f2_57_2968=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Headache phenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cerebral venous sinus thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Spontaneous cerebrospinal fluid leak headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Idiopathic intracranial hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Giant cell arteritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Primary headache disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/3343\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/3343|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/14/34027\" title=\"table 1\">",
"      Chronic migraine diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/22/39275\" title=\"table 2\">",
"      Chronic tension-type headache criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/35/8763\" title=\"table 3\">",
"      Medication overuse headache criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/56/30603\" title=\"table 4\">",
"      Hemicrania continua diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/48/35595\" title=\"table 5\">",
"      New daily persistent headache criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34599?source=related_link\">",
"      Diagnosis of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=related_link\">",
"      Etiology, clinical features, and diagnosis of cerebral venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43942?source=related_link\">",
"      Hemicrania continua",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17417?source=related_link\">",
"      Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18490?source=related_link\">",
"      Management of migraine headache in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/48/17161?source=related_link\">",
"      Medication overuse headache: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37830?source=related_link\">",
"      Overview of chronic daily headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/20/330?source=related_link\">",
"      Pathophysiology, clinical features, and diagnosis of spontaneous low cerebrospinal fluid pressure headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=related_link\">",
"      Preventive treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1433?source=related_link\">",
"      Tension-type headache in adults: Preventive treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34744?source=related_link\">",
"      Tension-type headache in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13126?source=related_link\">",
"      Treatment and prognosis of spontaneous low cerebrospinal fluid pressure headache",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_57_2969="Chagas disease: Management of acute disease, early chronic disease, and disease in immunocompromised hosts";
var content_f2_57_2969=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chagas disease: Management of acute disease, early chronic disease, and disease in immunocompromised hosts",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/57/2969/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/57/2969/contributors\">",
"     Caryn Bern, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/57/2969/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/57/2969/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/57/2969/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/57/2969/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/57/2969/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H107060869\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chagas disease is caused by infection with the protozoan parasite Trypanosoma cruzi. Issues related to management of acute Chagas, congenital Chagas, chronic Chagas, and Chagas in the setting of immunosuppression are reviewed here. The approach to antitrypanosomal therapy for Chagas disease varies by phase and form of disease (",
"    <a class=\"graphic graphic_table graphicRef65745 \" href=\"UTD.htm?24/43/25276\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef54443 \" href=\"UTD.htm?17/19/17723\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Management of cardiac and gastrointestinal manifestations of chronic Chagas disease is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16742?source=see_link\">",
"     \"Gastrointestinal Chagas disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16184?source=see_link&amp;anchor=H372251508#H372251508\">",
"     \"Treatment and prognosis of Chagas heart disease\", section on 'Management'",
"    </a>",
"    ). Dosing and adverse effects for antitrypanosomal drugs are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14356?source=see_link\">",
"     \"Antitrypanosomal drug therapy for Chagas disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107060876\">",
"    <span class=\"h1\">",
"     ACUTE CHAGAS DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history and diagnosis of acute and congenital Chagas disease are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/34/551?source=see_link&amp;anchor=H541206326#H541206326\">",
"     \"Chagas disease: Natural history and diagnosis\", section on 'Acute phase'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antitrypanosomal therapy with benznidazole or nifurtimox can reduce the severity of symptoms, shorten the clinical course, and reduce the duration of detectable parasitemia in acute and early congenital Chagas disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. In the acute phase, parasitological cure (as well as clinical cure) is thought to occur in 60 to 85 percent of patients treated [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among congenitally infected infants treated in the first year of life, parasitological cure is thought to occur in &gt;90 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/1,4-6\">",
"     1,4-6",
"    </a>",
"    ]. Treatment of infected infants should be initiated as soon as the diagnosis is made; the drugs are well tolerated in infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/1,7,8\">",
"     1,7,8",
"    </a>",
"    ]. Successful treatment is assumed to decrease or eliminate risk of later complications, although longitudinal data are lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of an infant or young child requires benznidazole or nifurtimox tablets to be crushed and prepared as a syrup or slurry in a compounding pharmacy to provide the appropriate dosage. A pediatric liquid formulation of benznidazole is under development [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/11\">",
"     11",
"    </a>",
"    ]. Dosing and adverse effects for antitrypanosomal drugs are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14356?source=see_link\">",
"     \"Antitrypanosomal drug therapy for Chagas disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the setting of acute and early congenital T. cruzi infection, treatment success can be monitored by PCR and direct examination of blood or buffy coat [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107060891\">",
"    <span class=\"h1\">",
"     CHRONIC CHAGAS DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107060900\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the diagnosis of chronic T. cruzi infection is confirmed by serologic testing, the initial evaluation consists of medical history, including a thorough review of systems with an emphasis on symptoms suggestive of cardiac arrhythmia, early congestive heart failure, thromboembolism, and gastrointestinal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/13\">",
"     13",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Social history should include details related to potential means of exposure to the parasite in endemic areas, via blood transfusion or other routes. Clinical evaluation should begin with complete physical examination",
"    <strong>",
"    </strong>",
"    and resting 12-lead electrocardiogram with a 30 second lead II rhythm strip [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further evaluation should be based on clinical findings. Patients with symptoms or ECG changes consistent with Chagas cardiomyopathy should undergo a comprehensive cardiac evaluation. Asymptomatic patients with non-specific findings on the ECG should have determination of need for further evaluation assessed on an individual basis by the treating clinician. Patients with symptoms consistent with gastrointestinal Chagas disease should undergo",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    studies and other evaluation as indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14266?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Chagas heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16742?source=see_link\">",
"     \"Gastrointestinal Chagas disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infected individuals should be counseled not to donate blood. Diagnostic screening should be offered for family members with a similar history of potential exposure to the parasite in endemic settings and all children of infected women [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11498?source=see_link&amp;anchor=H13#H13\">",
"     \"Blood donor medical history\", section on 'Chagas disease and babesiosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107060907\">",
"    <span class=\"h2\">",
"     Antitrypanosomal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few rigorous clinical trials of antitrypanosomal therapy in chronic T. cruzi infection have been conducted [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. A major barrier to such trials is the lack of a true test of cure. The length of time required for serologic test results to become negative following treatment is thought to be proportional to the duration of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/19\">",
"     19",
"    </a>",
"    ]. Seroconversion to negative using conventional assays such as ELISA or IFA is estimated to require an average of 3 to 5 years for those treated in the acute phase, 5 to 10 years in those with &lt;10 years duration, and 15 to 20 years in those with 10 years or more duration of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/19\">",
"     19",
"    </a>",
"    ]. Because most individuals who grew up in an area with endemic vector-borne transmission become infected as children, patient age is often used a proxy for the presumed duration of infection. Currently there is no practical method to assess treatment success in the chronic phase.",
"   </p>",
"   <p>",
"    There is a broad consensus that all children 18 years or younger with chronic T. cruzi infection should receive antitrypanosomal treatment. This was initially illustrated in two randomized trials conducted in the 1990s among children 6 to 12 years old with asymptomatic chronic T. cruzi infection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The efficacy of benznidazole over placebo was about 60 percent, as demonstrated by conversion from seropositive to seronegative three to four years after the end of treatment. However these trials each used a different experimental serologic assay, neither of which is widely available. In one of these studies, 90 percent of treated children remained positive by conventional serological tests four years after treatment, though generally with lower titers of antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/20\">",
"     20",
"    </a>",
"    ]. In the same trial, treated children also had a marked reduction in positive xenodiagnoses compared with the placebo group [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/20\">",
"     20",
"    </a>",
"    ]. Benznidazole was well-tolerated.",
"   </p>",
"   <p>",
"    In 2006, benznidazole treatment in adults was shown to slow the progression of Chagas cardiomyopathy and decrease mortality in a non-randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/22\">",
"     22",
"    </a>",
"    ]. Among 566 patients, fewer treated patients had progression of disease or EKG abnormalities compared with untreated patients (4 versus 14 percent and 5 versus 16 percent, respectively). Based on these data, and growing clinical experience in Latin America, most experts have come to favor antitrypanosomal treatment of adults with the indeterminate form of chronic T. cruzi infection and those with early signs of cardiomyopathy (eg, ECG changes in the absence of congestive heart failure) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/14,22-25\">",
"     14,22-25",
"    </a>",
"    ]. A randomized trial of benznidazole for adults with mild to moderate Chagas cardiomyopathy is underway [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Data from this study should help clarify treatment decisions for this group of patients. Antitrypanosomal therapy should be considered on an individual basis for individuals older than 50 years, since the risk of drug toxicity may be higher than in younger adults [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/14,28\">",
"     14,28",
"    </a>",
"    ]. Stronger consideration of treatment may be warranted for women of reproductive age since drug treatment likely reduces the probability of congenital transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with gastrointestinal Chagas disease, there are no data to suggest that antitrypanosomal therapy alters the course of illness; management focuses on symptom amelioration [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/21\">",
"     21",
"    </a>",
"    ]. The choice of antitrypanosomal therapy in these patients should be based on the likelihood of reducing risk of development or progression of heart disease. The factors outlined above, including age and possibility of congenital transmission, are relevant considerations. Drug absorption may be impaired in patients with megaesophagus; treatment should be delayed until after corrective surgical intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16742?source=see_link\">",
"     \"Gastrointestinal Chagas disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antitrypanosomal therapy is not warranted for patients with advanced Chagas cardiac disease, as the available drugs are not effective for reversal of existing pathology. In such patients, the focus of management is supportive care for heart failure, arrhythmia, and thromboembolism [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14266?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Chagas heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antitrypanosomal agents are contraindicated in pregnancy and in patients with severe renal or hepatic dysfunction. Dosing and adverse effects for antitrypanosomal drugs are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14356?source=see_link\">",
"     \"Antitrypanosomal drug therapy for Chagas disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107060914\">",
"    <span class=\"h1\">",
"     IMMUNOSUPPRESSION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3234161\">",
"    <span class=\"h2\">",
"     Chagas reactivation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactivation of chronic T. cruzi infection can occur in patients with immunosuppression due to malignancy, chemotherapy, immunosuppressive regimens for solid organ or bone marrow transplantation, or",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/12,31-41\">",
"     12,31-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reactivation may occur in the absence of specific symptoms or may present with manifestations that differ from those of acute infection. Transplant recipients may present with febrile episodes, symptoms suggestive of rejection,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dermatologic manifestations, including inflammatory panniculitis and skin nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/31,38,39\">",
"     31,38,39",
"    </a>",
"    ]. T. cruzi organisms may be demonstrable in skin lesions; impression smears",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stained biopsy specimens should be obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/42\">",
"     42",
"    </a>",
"    ]. Central nervous system (CNS) involvement can occur in transplant recipients with reactivation, but is less frequent than among patients with reactivation attributable to AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/35,39,40\">",
"     35,39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reactivation is characterized by a return to high levels of parasite replication similar to those seen in acute infection; circulating trypomastigotes can be detected by light microscopy of fresh whole blood or buffy coat [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/38,41\">",
"     38,41",
"    </a>",
"    ]. Quantitative PCR assays (eg, real time PCR) performed on serial specimens are useful to monitor for reactivation in the immunosuppressed T. cruzi-infected host. A positive result on conventional PCR does not prove reactivation but quantitative PCR assays that indicate rising parasite numbers over time provide the earliest and most sensitive indicator of reactivation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/12,43\">",
"     12,43",
"    </a>",
"    ]. Additional issues related to laboratory diagnosis of Chagas disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/34/551?source=see_link&amp;anchor=H541206387#H541206387\">",
"     \"Chagas disease: Natural history and diagnosis\", section on 'Laboratory diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study of 23 renal transplant recipients in Argentina followed for up to seven years, five patients were diagnosed with reactivation based on parasitemia (21 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/31\">",
"     31",
"    </a>",
"    ]. Of these patients, two had skin lesions and one of these also had panniculitis; the other three patients were asymptomatic. Reactivation was diagnosed 35 to 97 days post-transplant in four of the five patients; the fifth had reactivation detected 29 months after transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3234189\">",
"    <span class=\"h3\">",
"     HIV/AIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactivation of T. cruzi infection in the setting of",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    can cause severe disease with high risk of mortality. Among 53 patients with HIV and T. cruzi infection followed for 1 to 190 months in one series, T. cruzi reactivation was observed in 21 percent of patients; the diagnosis was established based on symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    positive peripheral blood smear [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/41\">",
"     41",
"    </a>",
"    ]. Among patients without clinical manifestations of reactivation, the level of parasitemia is higher among patients with HIV coinfection than HIV seronegative individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most commonly reported manifestations of symptomatic T. cruzi reactivation in patients with AIDS are meningoencephalitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    T. cruzi brain abscesses (chagomas). The presentation may be confused with CNS toxoplasmosis and should be considered in the differential diagnosis of AIDS patients with CNS symptoms or mass lesions on imaging (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82194 \" href=\"UTD.htm?2/43/2738\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/41,45,46\">",
"     41,45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The second most common reported manifestation of reactivation in",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    patients is acute myocarditis, sometimes superimposed on preexisting chronic Chagas heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/41,47\">",
"     41,47",
"    </a>",
"    ]. Patients may present with new arrhythmias, pericardial effusions, acute cardiac decompensation, or accelerated progression of existing chronic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/41,48\">",
"     41,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute meningoencephalitis and myocarditis can occur simultaneously. In one Brazilian cohort, cardiac reactivation was as frequent as CNS disease; reactivation may be subtle and can mimic progression of chronic Chagas cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other manifestations of Chagas reactivation in the setting of",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    include skin lesions, erythema nodosum, and parasitic invasion of the peritoneum, stomach, or intestine [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/44,48\">",
"     44,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3234196\">",
"    <span class=\"h3\">",
"     Treatment and prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal approach to treatment of Chagas disease in immunocompromised patients and the efficacy of secondary prophylaxis remain uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/49\">",
"     49",
"    </a>",
"    ]. Data are limited to observational studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among transplant patients with reactivated infection, treatment with benznidazole accelerated improvement in clinical symptoms and reduced intensity of parasitemia [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/31,35,39,50\">",
"       31,35,39,50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a small series of patients with HIV and T. cruzi coinfection, a course of benznidazole therapy resulted in improvement of clinical manifestations and decreased parasitemia [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reactivation should be managed with standard courses of antitrypanosomal treatment. For patients with AIDS, antiretroviral therapy should be optimized [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/49\">",
"     49",
"    </a>",
"    ]. Dosing and adverse effects for antitrypanosomal drugs are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14356?source=see_link\">",
"     \"Antitrypanosomal drug therapy for Chagas disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antitrypanosomal therapy is not generally advised for patients at risk of reactivation (such as patients with HIV coinfection and patients with previously untreated T. cruzi infection awaiting organ transplant) because treatment is unlikely to be curative in this setting and carries substantial risk of adverse effects. Close monitoring is warranted with initiation of antitrypanosomal therapy if reactivation is demonstrated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3232739\">",
"    <span class=\"h2\">",
"     Organ transplant",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107060922\">",
"    <span class=\"h3\">",
"     Donor transmission in organ transplant recipients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organ transplant recipients who receive an organ from a donor infected with T. cruzi may develop acute T. cruzi infection, although transmission under these circumstances appears to be fairly uncommon. In series of 16 recipients of kidney transplants from infected donors, only three acquired T. cruzi infection (19 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/31\">",
"     31",
"    </a>",
"    ]. Only 20 instances of transmission by organ transplantation have been documented in the literature (14 kidney, one kidney and pancreas, three liver, two heart transplants) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/31,51-59\">",
"     31,51-59",
"    </a>",
"    ]. However, hearts from known infected donors are never transplanted in Latin America; all such transplants have occurred in the United States from donors with unknown infection status at the time of the transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/52\">",
"     52",
"    </a>",
"    ]. Two of the three heart recipients became infected; based on these sparse data and the known tropism of the parasite, the transmission risk is likely higher than for other organs [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/52\">",
"     52",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Among the 10 organ recipients for whom data were available in published reports, the period from transplantation to onset of symptoms of acute T. cruzi infection ranged from 23 to 300 days (mean 103 days; median 62 days). Symptoms included fever, malaise, anorexia, hepatosplenomegaly, acute myocarditis, and decreased cardiac function. Two of the 18 reported patients presented with fulminant myocarditis and congestive heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/51,59\">",
"     51,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Identification of donor infection following organ transplantation should prompt careful post-transplant monitoring of the recipients; routine presumptive antitrypanosomal treatment is not generally warranted. Seroconversion may be delayed or never occur in immunocompromised individuals, and establishing the presence or absence of infection is important for long term management; presumptive treatment would preclude this evaluation. Patients whose infection is detected early through monitoring have excellent response to treatment and good clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Monitoring consists of evaluation for evidence of infection by microscopy, culture, and PCR, if available. PCR has the highest sensitivity but requires a specialized laboratory. In the United States, the Centers for Disease Control (CDC) acts as a reference laboratory for T. cruzi PCR (Division of Parasitic Diseases Public Inquiries line, 404-718-4745; for emergencies after business hours, 770-488-7100; email parasites@cdc.gov). Microscopy should be performed on a fresh specimen in the first one to two hours after collection, when trypomastigotes are still motile and therefore more readily detected. Monitoring should consist of weekly specimens for two months, every two weeks for the third month, and then monthly until six months post-transplantation, when the monitoring interval can be lengthened if no evidence of infection has been detected. In the case of febrile episodes or suspected rejection, additional specimens should be evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/31,52,58\">",
"     31,52,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional issues related to laboratory diagnosis of Chagas disease are discussed separately. Dosing and adverse effects for antitrypanosomal drugs are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/34/551?source=see_link&amp;anchor=H541206387#H541206387\">",
"     \"Chagas disease: Natural history and diagnosis\", section on 'Laboratory diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14356?source=see_link\">",
"     \"Antitrypanosomal drug therapy for Chagas disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3233106\">",
"    <span class=\"h3\">",
"     Heart transplantation for Chagas cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic T. cruzi infection may be considered as candidates for organ transplantation. In a large cohort of heart transplant patients, survival of those who underwent transplantation for management of chronic Chagas cardiomyopathy was higher than survival among those with other etiologies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. In the most rigorous cohort study, post-operative survival at 1, 4, 8, and 12 years was 71, 57, 55, and 46 percent for those transplanted for Chagas cardiomyopathy, compared with 69, 57, 40, and 32 percent for idiopathic dilated cardiomyopathy, and 59, 44, 34, and 22 percent for ischemic heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/60\">",
"     60",
"    </a>",
"    ]. Death due to reactivation of T. cruzi reactivation was rare (1.7 percent); causes of death were comparable to those for patients with other transplant indications (eg, other infections, rejection) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some experts favor administration of antitrypanosomal therapy prior to the induction of immunosuppression, even though such treatment appears to achieve cure in few patients with longstanding chronic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/38\">",
"     38",
"    </a>",
"    ]. Therefore, treated individuals are still considered to be at risk for reactivation. Dosing and adverse effects for antitrypanosomal drugs are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14356?source=see_link\">",
"     \"Antitrypanosomal drug therapy for Chagas disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among heart transplant recipients, reactivation may be diagnosed based on detection of parasites on peripheral blood smears, rising parasite load by quantitative PCR",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    findings of acute Chagas myocarditis observed on routine endomyocardial biopsies performed at regular intervals to monitor for graft rejection. The characteristic findings consist of T. cruzi amastigotes with or without surrounding inflammatory infiltrate (",
"    <a class=\"graphic graphic_picture graphicRef52549 \" href=\"UTD.htm?37/61/38870\">",
"     picture 1",
"    </a>",
"    ). These findings may occur in the absence of microscopically detectable peripheral parasitemia and may precede development of clinical signs of myocarditis.",
"   </p>",
"   <p>",
"    The cumulative risk of reactivation among heart transplant patients in published cohort studies ranges from 29 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/12,36-39,63,64\">",
"     12,36-39,63,64",
"    </a>",
"    ]. Reactivation was diagnosed at times varying from 38 days to more than seven years after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/12,38\">",
"     12,38",
"    </a>",
"    ]. Risk factors associated with increased risk of reactivation included use of high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    A or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, frequent rejection episodes, and neoplasm [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3233113\">",
"    <span class=\"h4\">",
"     Monitoring for reactivation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the timing of monitoring for T. cruzi reactivation should follow the same schedule used for rejection monitoring (eg, 1, 3, 6, 9, and 12 months after transplantation, plus 1 month after steroid treatment for rejection and when fever or other symptoms occur) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/38\">",
"     38",
"    </a>",
"    ]. Evidence of reactivation should be sought in routine endomyocardial biopsies, peripheral blood examination and, if available, by quantitative PCR. As noted above, a positive PCR result is not sufficient for diagnosis of reactivation. The most sensitive indicator of reactivation is the demonstration of rising parasite numbers by quantitative PCR in serial specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2969/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107060964\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most congenital T. cruzi infections are asymptomatic or cause non-specific signs; laboratory screening is required for detection. In a small proportion of patients, congenital infection causes severe morbidity including low birthweight, hepatosplenomegaly, anemia, meningoencephalitis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      respiratory insufficiency. Most Chagas disease control programs in Latin America employ prenatal serological screening followed by testing of the newborns of infected mothers. (See",
"      <a class=\"local\" href=\"#H107060876\">",
"       'Acute Chagas disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial evaluation of patients with suspected chronic T. cruzi infection consists of thorough medical history with an emphasis on symptoms suggestive of cardiac arrhythmia or conduction system defect, early congestive heart failure, thromboembolism, and gastrointestinal disease.",
"      <strong>",
"      </strong>",
"      Social history should include details related to potential means of exposure to the parasite in endemic areas or via blood transfusion or other routes. Clinical evaluation should begin with complete physical examination",
"      <strong>",
"      </strong>",
"      and resting 12-lead electrocardiogram with a 30 second lead II rhythm strip. Further evaluation should be based on clinical findings. (See",
"      <a class=\"local\" href=\"#H107060900\">",
"       'Initial evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reactivation of chronic T. cruzi infection can occur in patients with immunosuppression due to malignancy, chemotherapy, immunosuppressive regimens for solid organ or bone marrow transplantation, or",
"      <span class=\"nowrap\">",
"       HIV/AIDS.",
"      </span>",
"      The diagnosis of reactivation requires detection of circulating trypomastigotes in the peripheral blood; quantitative polymerase chain reaction (PCR) on serial specimens is a useful technique to show rising parasite load. A positive result on conventional PCR does not prove reactivation but quantitative PCR assays that indicate rising parasite numbers over time provide the earliest and most sensitive indicator of reactivation. (See",
"      <a class=\"local\" href=\"#H3234161\">",
"       'Chagas reactivation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Organ transplant recipients who receive an organ from a donor infected with T. cruzi may develop acute T. cruzi infection, although transmission under these circumstances appears to be fairly uncommon. Sparse data suggest that transmission risk is likely higher for heart transplants than for other organs. Identification of infection in the donor following organ transplantation should prompt careful post transplant monitoring of recipients with serial specimens for microscopy and PCR; routine presumptive treatment is not generally warranted. (See",
"      <a class=\"local\" href=\"#H107060922\">",
"       'Donor transmission in organ transplant recipients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The approach to antitrypanosomal therapy for Chagas disease varies by phase and form of disease (",
"      <a class=\"graphic graphic_table graphicRef65745 \" href=\"UTD.htm?24/43/25276\">",
"       table 1",
"      </a>",
"      ). We recommend antitrypanosomal therapy in the setting of acute infection, congenital infection, and chronic infection among patients &le;18 years of age [(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ) for patients &le;12 years; (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ) for patients 13 to 18 years]. We also recommend antitrypanosomal therapy in the setting of reactivated infection (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest antitrypanosomal therapy for individuals between 19 and 50 years of age without advanced Chagas cardiomyopathy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Antitrypanosomal therapy should be considered on an individual basis for individuals older than 50 years, since the risk of drug toxicity may be higher than in younger adults. (See",
"      <a class=\"local\" href=\"#H107060876\">",
"       'Acute Chagas disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H107060907\">",
"       'Antitrypanosomal therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3234161\">",
"       'Chagas reactivation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest NOT administering antitrypanosomal therapy for patients with advanced Chagas cardiac disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The available drugs are not effective for reversal of existing pathology; in such patients the focus of management is supportive care for heart failure, arrhythmia, and thromboembolism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16184?source=see_link&amp;anchor=H372251508#H372251508\">",
"       \"Treatment and prognosis of Chagas heart disease\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest NOT administering pre-emptive antitrypanosomal therapy for patients at risk of reactivation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Close monitoring is warranted with initiation of antitrypanosomal therapy if reactivation is demonstrated. (See",
"      <a class=\"local\" href=\"#H3234196\">",
"       'Treatment and prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In acute, congenital, or reactivated infection, response to treatment can be assessed using molecular methods, including quantitative PCR. Thus far there is no practical method to assess response to treatment in the chronic phase. (See",
"      <a class=\"local\" href=\"#H107060876\">",
"       'Acute Chagas disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H107060914\">",
"       'Immunosuppression'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H107060891\">",
"       'Chronic Chagas disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/1\">",
"      Wegner DH, Rohwedder RW. The effect of nifurtimox in acute Chagas' infection. Arzneimittelforschung 1972; 22:1624.",
"     </a>",
"    </li>",
"    <li>",
"     Magill AJ, Reed SG. American Trypanosomiasis. In: Hunter's Tropical Medicine and Emerging Deseases, 8th ed, Strickland GT (Ed), W.B. Saunders Company, Philadelphia 2000. p.653.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/3\">",
"      Kirchhoff LV. Chagas disease. American trypanosomiasis. Infect Dis Clin North Am 1993; 7:487.",
"     </a>",
"    </li>",
"    <li>",
"     Cancado JR, Brener Z. Terapeutica. In: Trypanosoma cruzi e doen&ccedil;a de Chagas, 1st ed, Guanabara Koogan, Rio de Janeiro, Brazil 1979. p.362.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/5\">",
"      Rodriques Coura J, de Castro SL. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 2002; 97:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/6\">",
"      Altcheh J, Biancardi M, Lape&ntilde;a A, et al. [Congenital Chagas disease: experience in the Hospital de Ni&ntilde;os, Ricardo Guti&eacute;rrez, Buenos Aires, Argentina]. Rev Soc Bras Med Trop 2005; 38 Suppl 2:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/7\">",
"      Russomando G, de Tomassone MM, de Guillen I, et al. Treatment of congenital Chagas' disease diagnosed and followed up by the polymerase chain reaction. Am J Trop Med Hyg 1998; 59:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/8\">",
"      Centers for Disease Control and Prevention (CDC). Congenital transmission of Chagas disease - Virginia, 2010. MMWR Morb Mortal Wkly Rep 2012; 61:477.",
"     </a>",
"    </li>",
"    <li>",
"     Schijman AG. Congenital Chagas Disease. In: Congenital and Other Related Infectious Diseases of the Newborn, Mushahwar IK (Ed), Elsevier, Amsterdam, Netherlands 2006. Vol 13, p.223.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/10\">",
"      Freilij H, Altcheh J. Congenital Chagas' disease: diagnostic and clinical aspects. Clin Infect Dis 1995; 21:551.",
"     </a>",
"    </li>",
"    <li>",
"     Drugs for Neglected Disease Initiative. Chagas disease: DNDi Strategy, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/12\">",
"      Diez M, Favaloro L, Bertolotti A, et al. Usefulness of PCR strategies for early diagnosis of Chagas' disease reactivation and treatment follow-up in heart transplantation. Am J Transplant 2007; 7:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/13\">",
"      Bern C. Antitrypanosomal therapy for chronic Chagas' disease. N Engl J Med 2011; 364:2527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/14\">",
"      Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA 2007; 298:2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/15\">",
"      L&aacute;zzari JO, Pereira M, Antunes CM, et al. Diagnostic electrocardiography in epidemiological studies of Chagas' disease: multicenter evaluation of a standardized method. Rev Panam Salud Publica 1998; 4:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/16\">",
"      P&eacute;rez-Molina JA, P&eacute;rez-Ayala A, Moreno S, et al. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. J Antimicrob Chemother 2009; 64:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/17\">",
"      Reyes PA, Vallejo M. Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection). Cochrane Database Syst Rev 2005; :CD004102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/18\">",
"      Villar JC, Marin-Neto JA, Ebrahim S, Yusuf S. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst Rev 2002; :CD003463.",
"     </a>",
"    </li>",
"    <li>",
"     Rassi A, Luquetti AO. Specific treatment for Trypanosoma cruzi infection (Chagas disease).. In: American Trypanosomiasis, Miles MA, Tyler KM (Eds), Kluwer Academic Publishers, Boston 2003. p.117.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/20\">",
"      Sosa Estani S, Segura EL, Ruiz AM, et al. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg 1998; 59:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/21\">",
"      de Andrade AL, Zicker F, de Oliveira RM, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996; 348:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/22\">",
"      Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006; 144:724.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Expert Committee. Control of Chagas Disease. World Health Organization, Brasilia, Brazil 2002. p. 1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/24\">",
"      Minist&eacute;rio da Sa&uacute;de. Secretaria de Vigil&acirc;ncia em Sa&uacute;de. [Brazilian Consensus on Chagas disease]. Rev Soc Bras Med Trop 2005; 38 Suppl 3:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/25\">",
"      Sosa-Estani S, Segura EL. Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina. Curr Opin Infect Dis 2006; 19:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/26\">",
"      Marin-Neto JA, Rassi A Jr, Morillo CA, et al. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J 2008; 156:37.",
"     </a>",
"    </li>",
"    <li>",
"     file://clinicaltrials.gov/show/NCT00123916 (Accessed on October 07, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/28\">",
"      Wegner DH, Rohwedder RW. Experience with nifurtimox in chronic Chagas' infection. Preliminary report. Arzneimittelforschung 1972; 22:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/29\">",
"      Sosa-Estani S, Cura E, Velazquez E, et al. Etiological treatment of young women infected with Trypanosoma cruzi, and prevention of congenital transmission. Rev Soc Bras Med Trop 2009; 42:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/30\">",
"      Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet 2010; 375:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/31\">",
"      Riarte A, Luna C, Sabatiello R, et al. Chagas' disease in patients with kidney transplants: 7 years of experience 1989-1996. Clin Infect Dis 1999; 29:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/32\">",
"      Fontes Rezende RE, Lescano MA, Zambelli Ramalho LN, et al. Reactivation of Chagas' disease in a patient with non-Hodgkin's lymphoma: gastric, oesophageal and laryngeal involvement. Trans R Soc Trop Med Hyg 2006; 100:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/33\">",
"      Kohl S, Pickering LK, Frankel LS, Yaeger RG. Reactivation of Chagas' disease during therapy of acute lymphocytic leukemia. Cancer 1982; 50:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/34\">",
"      Metze K, Lorand-Metze I, De Almeida EA, De Moraes SL. Reactivation of Chagas' myocarditis during therapy of Hodgkin's disease. Trop Geogr Med 1991; 43:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/35\">",
"      Altclas J, Sinagra A, Dictar M, et al. Chagas disease in bone marrow transplantation: an approach to preemptive therapy. Bone Marrow Transplant 2005; 36:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/36\">",
"      Bacal F, Silva CP, Bocchi EA, et al. Mychophenolate mofetil increased chagas disease reactivation in heart transplanted patients: comparison between two different protocols. Am J Transplant 2005; 5:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/37\">",
"      Bocchi EA, Bellotti G, Mocelin AO, et al. Heart transplantation for chronic Chagas' heart disease. Ann Thorac Surg 1996; 61:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/38\">",
"      Campos SV, Strabelli TM, Amato Neto V, et al. Risk factors for Chagas' disease reactivation after heart transplantation. J Heart Lung Transplant 2008; 27:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/39\">",
"      Fiorelli AI, Stolf NA, Honorato R, et al. Later evolution after cardiac transplantation in Chagas' disease. Transplant Proc 2005; 37:2793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/40\">",
"      Marchiori PE, Alexandre PL, Britto N, et al. Late reactivation of Chagas' disease presenting in a recipient as an expansive mass lesion in the brain after heart transplantation of chagasic myocardiopathy. J Heart Lung Transplant 2007; 26:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/41\">",
"      Sartori AM, Ibrahim KY, Nunes Westphalen EV, et al. Manifestations of Chagas disease (American trypanosomiasis) in patients with HIV/AIDS. Ann Trop Med Parasitol 2007; 101:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/42\">",
"      Gallerano V, Consigli J, Pereyra S, et al. Chagas' disease reactivation with skin symptoms in a patient with kidney transplant. Int J Dermatol 2007; 46:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/43\">",
"      Duffy T, Bisio M, Altcheh J, et al. Accurate real-time PCR strategy for monitoring bloodstream parasitic loads in chagas disease patients. PLoS Negl Trop Dis 2009; 3:e419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/44\">",
"      Sartori AM, Neto JE, Nunes EV, et al. Trypanosoma cruzi parasitemia in chronic Chagas disease: comparison between human immunodeficiency virus (HIV)-positive and HIV-negative patients. J Infect Dis 2002; 186:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/45\">",
"      Cordova E, Boschi A, Ambrosioni J, et al. Reactivation of Chagas disease with central nervous system involvement in HIV-infected patients in Argentina, 1992-2007. Int J Infect Dis 2008; 12:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/46\">",
"      Diazgranados CA, Saavedra-Trujillo CH, Mantilla M, et al. Chagasic encephalitis in HIV patients: common presentation of an evolving epidemiological and clinical association. Lancet Infect Dis 2009; 9:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/47\">",
"      Vaidian AK, Weiss LM, Tanowitz HB. Chagas' disease and AIDS. Kinetoplastid Biol Dis 2004; 3:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/48\">",
"      Ferreira MS, Nishioka Sde A, Silvestre MT, et al. Reactivation of Chagas' disease in patients with AIDS: report of three new cases and review of the literature. Clin Infect Dis 1997; 25:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/49\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/50\">",
"      Maldonado C, Albano S, Vettorazzi L, et al. Using polymerase chain reaction in early diagnosis of re-activated Trypanosoma cruzi infection after heart transplantation. J Heart Lung Transplant 2004; 23:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/51\">",
"      Centers for Disease Control and Prevention (CDC). Chagas disease after organ transplantation--United States, 2001. MMWR Morb Mortal Wkly Rep 2002; 51:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/52\">",
"      Kun H, Moore A, Mascola L, et al. Transmission of Trypanosoma cruzi by heart transplantation. Clin Infect Dis 2009; 48:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/53\">",
"      Chocair PR, Sabbaga E, Amato Neto V, et al. [Kidney transplantation: a new way of transmitting chagas disease]. Rev Inst Med Trop Sao Paulo 1981; 23:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/54\">",
"      de Arteaga J, Massari PU, Galli B, et al. Renal transplantation and Chagas' disease. Transplant Proc 1992; 24:1900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/55\">",
"      de Faria JB, Alves G. Transmission of Chagas' disease through cadaveric renal transplantation. Transplantation 1993; 56:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/56\">",
"      Ferraz AS, Figueiredo JF. Transmission of Chagas' disease through transplanted kidney: occurrence of the acute form of the disease in two recipients from the same donor. Rev Inst Med Trop Sao Paulo 1993; 35:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/57\">",
"      Figueiredo JF, Martinez R, da Costa JC, et al. Transmission of Chagas disease through renal transplantation: report of a case. Trans R Soc Trop Med Hyg 1990; 84:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/58\">",
"      Barc&aacute;n L, Luna C, Luna&oacute; C, et al. Transmission of T. cruzi infection via liver transplantation to a nonreactive recipient for Chagas' disease. Liver Transpl 2005; 11:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/59\">",
"      Souza FF, Castro-E-Silva O, Marin Neto JA, et al. Acute chagasic myocardiopathy after orthotopic liver transplantation with donor and recipient serologically negative for Trypanosoma cruzi: a case report. Transplant Proc 2008; 40:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/60\">",
"      Bocchi EA, Fiorelli A. The paradox of survival results after heart transplantation for cardiomyopathy caused by Trypanosoma cruzi. First Guidelines Group for Heart Transplantation of the Brazilian Society of Cardiology. Ann Thorac Surg 2001; 71:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/61\">",
"      Bocchi EA, Fiorelli A, First Guideline Group for Heart Transplantation of the Brazilian Society of Cardiology. The Brazilian experience with heart transplantation: a multicenter report. J Heart Lung Transplant 2001; 20:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/62\">",
"      Bestetti RB, Theodoropoulos TA. A systematic review of studies on heart transplantation for patients with end-stage Chagas' heart disease. J Card Fail 2009; 15:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/63\">",
"      de Carvalho VB, Sousa EF, Vila JH, et al. Heart transplantation in Chagas' disease. 10 years after the initial experience. Circulation 1996; 94:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2969/abstract/64\">",
"      Bocchi EA, Bellotti G, Uip D, et al. Long-term follow-up after heart transplantation in Chagas' disease. Transplant Proc 1993; 25:1329.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15237 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.111.122.2-0C8C6D5D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_57_2969=[""].join("\n");
var outline_f2_57_2969=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H107060964\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H107060869\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H107060876\">",
"      ACUTE CHAGAS DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H107060891\">",
"      CHRONIC CHAGAS DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107060900\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107060907\">",
"      Antitrypanosomal therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H107060914\">",
"      IMMUNOSUPPRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3234161\">",
"      Chagas reactivation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3234189\">",
"      - HIV/AIDS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3234196\">",
"      - Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3232739\">",
"      Organ transplant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H107060922\">",
"      - Donor transmission in organ transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3233106\">",
"      - Heart transplantation for Chagas cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3233113\">",
"      Monitoring for reactivation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H107060964\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/15237\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/15237|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/43/2738\" title=\"diagnostic image 1\">",
"      MRI of reactivated Chagas in the CNS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/15237|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/61/38870\" title=\"picture 1\">",
"      Heart biopsy with nest of amastigotes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/15237|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/43/25276\" title=\"table 1\">",
"      Treatment of Chagas disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/19/17723\" title=\"table 2\">",
"      Antitrypanosomal drugs dosing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14356?source=related_link\">",
"      Antitrypanosomal drug therapy for Chagas disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11498?source=related_link\">",
"      Blood donor medical history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/34/551?source=related_link\">",
"      Chagas disease: Natural history and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14266?source=related_link\">",
"      Clinical manifestations and diagnosis of Chagas heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16742?source=related_link\">",
"      Gastrointestinal Chagas disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16184?source=related_link\">",
"      Treatment and prognosis of Chagas heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_57_2970="Acute iron poisoning";
var content_f2_57_2970=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute iron poisoning",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/57/2970/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/57/2970/contributors\">",
"     Erica L Liebelt, MD, FACMT",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/57/2970/contributors\">",
"     Rana Kronfol, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/57/2970/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/57/2970/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/57/2970/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/57/2970/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/57/2970/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/57/2970/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute iron poisoning continues to be a common and potentially lethal ingestion, especially in the pediatric population. Early recognition is necessary to ensure appropriate therapy and prevention of fatalities.",
"   </p>",
"   <p>",
"    The epidemiology, pharmacology, clinical manifestations, evaluation, and management of acute iron ingestion are reviewed here. An overview of the evaluation and management is included (",
"    <a class=\"graphic graphic_table graphicRef61711 \" href=\"UTD.htm?8/44/8909\">",
"     table 1",
"    </a>",
"    ). Iron deficiency, iron requirements, and iron balance are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=see_link\">",
"     \"Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4329?source=see_link\">",
"     \"Iron requirements and iron deficiency in adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link\">",
"     \"Regulation of iron balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost 16,000 iron exposures annually are reported in children less than six years of age in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/1\">",
"     1",
"    </a>",
"    ]. Although the overall number of exposures in this age group has remained stable, the number of major effects and death in children are improved when compared to the period from 1990 to 2000.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Unintentional ingestion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of childhood iron poisonings are unintentional and result in no or minimal toxicity. The most serious exposures involve prenatal vitamins and pure iron preparations that contain",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37046?source=see_link\">",
"     ferrous sulfate",
"    </a>",
"    tablets, which typically have significantly more elemental iron per tablet (60 to 65 mg) than other iron preparations. These tablets appeal to children because they are often brightly colored, sugar-coated, and have the appearance of candy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. In one population-based case-control study, the birth of a sibling within six months was identified as a risk factor for iron poisoning in children younger than three years of age (adjusted odds ratio [OR] 1.9, 95% CI 0.9-3.9); the risk was greatest within the first postpartum month (adjusted OR 3.6, 95% CI 0.8-16.5) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children's chewable vitamins with iron are less likely than adult preparations to cause serious toxicity. There were no fatalities among 195,780 exposures to chewable children's vitamins with iron reported by the American Association of Poison Control Centers between 1983 and 1998 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/6\">",
"     6",
"    </a>",
"    ]. During the same time period, there were 60 deaths among 147,079 ingestions of adult preparations containing iron. (See",
"    <a class=\"local\" href=\"#H38\">",
"     'Home management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although the majority of patients treated for iron ingestion in healthcare facilities experience some toxicity, there has been a reduction in the number of fatalities from unintentional exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. This reduced fatality rate has been attributed to the implementation of preventive measures, particularly unit dose packaging, which followed several highly publicized deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/2,8,9\">",
"     2,8,9",
"    </a>",
"    ]. These regulations were unfortunately withdrawn in 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37944?source=see_link&amp;anchor=H10#H10\">",
"     \"Prevention of poisoning in children\", section on 'Primary prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with most unintentional ingestions, the best therapy is prevention. Child-resistant closures are required on vitamin bottles that contain more than 250 mg of elemental iron. Nevertheless, some intoxications involve packages or containers that are left open, improperly closed, or opened by a child [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. All medications should be kept in a safe place and stored in their original packaging or in child-resistant containers. Caregivers of children should be instructed to call their regional poison control center (1-800-222-1222) in the event of ingestion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Intentional ingestion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of intentional iron overdose differs from that of unintentional ingestion. In one institutional review of 113 cases of iron overdose requiring hospital admission, 58 percent were determined to be intentional (based upon information provided by the patient, family, or friends) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/11\">",
"     11",
"    </a>",
"    ]. Among the intentional ingestions, 80 percent occurred among females, with a mean age of 19.8 years. The mortality rate is increased among patients with intentional ingestion (10 percent in this series versus less than 1 percent for unintentional iron ingestions).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Iron preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron preparations are available most commonly in the form of iron salts. The amount of elemental iron in each preparation varies depending upon the salt form (",
"    <a class=\"graphic graphic_table graphicRef64634 \" href=\"UTD.htm?14/39/14973\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/37/38485?source=see_link\">",
"       Ferrous gluconate",
"      </a>",
"      (12 percent elemental iron)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37046?source=see_link\">",
"       Ferrous sulfate",
"      </a>",
"      (20 percent elemental iron)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7798?source=see_link\">",
"       Ferrous fumarate",
"      </a>",
"      (33 percent elemental iron)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Time-release formulations or enteric-coated iron preparations are available and may have delayed absorption. This is an important consideration when interpreting serum iron concentration. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Serum iron concentration'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Iron is an ingredient in many multiple-vitamin preparations. Prenatal vitamins typically contain 60 to 65 mg of elemental iron, whereas most multivitamin preparations contain 15 to 18 mg (",
"    <a class=\"graphic graphic_table graphicRef73372 \" href=\"UTD.htm?0/44/717\">",
"     table 3",
"    </a>",
"    ). The \"placebo\" row of some 28-day oral contraceptive pill packages may contain iron and are another potential source for accidental ingestion (eg, the placebo row of Loestrin&reg; Fe and Estrostep&reg; Fe each contain 75 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7798?source=see_link\">",
"     ferrous fumarate",
"    </a>",
"    [25 mg elemental iron]).",
"   </p>",
"   <p>",
"    Nonionic forms of iron include carbonyl iron and iron polysaccharide complex. Carbonyl iron is produced by vaporizing submicroscopic spheres of uncharged, highly purified metallic iron (Fe&ordm;). Fe&ordm; must be converted to Fe2+ by gastric acid before it can be absorbed. As a result, carbonyl iron is absorbed more slowly and has a higher bioavailability than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37046?source=see_link\">",
"     ferrous sulfate",
"    </a>",
"    . In addition, it has a greater safety margin than ferrous sulfate. There have been no published reports of serious or fatal poisoning from ingestion of carbonyl iron [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Iron polysaccharide complex is produced by the neutralization of ferric chloride-carbohydrate solution. It contains 46 percent elemental iron by weight and appears to be less toxic than ferrous salts. In one large retrospective series of iron polysaccharide complex overdose, there were no major effects or deaths reported [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Toxic dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The toxicity of iron depends upon the amount of elemental iron ingested. Various salt forms contain different percentages of elemental iron (",
"    <a class=\"graphic graphic_table graphicRef64634 \" href=\"UTD.htm?14/39/14973\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef73372 \" href=\"UTD.htm?0/44/717\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Iron preparations'",
"    </a>",
"    above.) As an example, a 15 kg child who ingests 10 tablets containing 325 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37046?source=see_link\">",
"     ferrous sulfate",
"    </a>",
"    each has ingested about 43",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of elemental iron.",
"   </p>",
"   <p>",
"    The minimum toxic dose and the lethal doses of iron are not firmly established. The following symptoms and toxicities have been reported at various doses:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who ingest less than 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of elemental iron are usually asymptomatic.",
"     </li>",
"     <li>",
"      Ingestions of 20 to 60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      may or may not produce symptoms of serious toxicity.",
"     </li>",
"     <li>",
"      A small number of patients who have taken 40 to 60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of iron are symptomatic. In one retrospective review of 199 acute iron exposures, none of the patients who ingested between 40 and 60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of iron developed serious toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ingestions of more than 60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      can be associated with serious toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/2,12,16,17\">",
"       2,12,16,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Death from iron toxicity has been reported from a wide range of doses (from 60 to 300",
"      <span class=\"nowrap\">",
"       mg/kg).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Iron toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ferric iron is toxic to a number of cellular processes. The primary mechanism for iron-induced tissue damage is free radical production and lipid peroxidation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/18\">",
"     18",
"    </a>",
"    ]. Toxic effects on cells include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/12,16,19,20\">",
"     12,16,19,20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mucosal cell necrosis",
"     </li>",
"     <li>",
"      Impairment of capillary permeability",
"     </li>",
"     <li>",
"      Alteration of the lipid membrane of mitochondria",
"     </li>",
"     <li>",
"      Inhibition of enzymatic processes in the Krebs cycle",
"     </li>",
"     <li>",
"      Uncoupling of oxidative phosphorylation",
"     </li>",
"     <li>",
"      Direct vasodilation",
"     </li>",
"     <li>",
"      Inhibition of serum proteases (eg, thrombin)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Normally, transferrin (the chief iron binding protein in plasma) and ferritin (an iron storage protein that sequesters iron intracellularly) protect cells by binding iron, limiting the amount that is circulating in the ferric state. However, these protective mechanisms become quickly overwhelmed with an acute intoxication [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Local toxicity (manifested as abdominal pain, vomiting, diarrhea, and gastrointestinal bleeding) develops from iron-induced damage to the gastrointestinal mucosa. Systemic toxicity occurs as the result of injury to the cardiovascular system and liver. The cause of death from iron poisoning is usually shock or liver failure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Clinical manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Kinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron is absorbed primarily in the duodenum and upper jejunum. It crosses cell membranes only in the ferrous state (Fe2+). Once absorbed by the mucosal cells, iron is oxidized to the ferric (Fe3+) form. From the enterocyte, iron is released into the plasma and bound to transferrin.",
"   </p>",
"   <p>",
"    After therapeutic dosing, 10 to 35 percent of iron is absorbed. As much as 80 to 95 percent may be absorbed in iron-deficient patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/18,21\">",
"     18,21",
"    </a>",
"    ]. The absorption of enteric-coated preparations is less than that of nonenteric-coated preparations.",
"   </p>",
"   <p>",
"    The amount of iron that is absorbed in an overdose situation is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/19\">",
"     19",
"    </a>",
"    ]. Physiologic regulation of iron absorption is lost in the setting of excessive iron ingestions. In addition, normal protective mechanisms (transport and storage proteins) become saturated, resulting in more free circulating iron (which is responsible for cellular toxicity).",
"   </p>",
"   <p>",
"    Peak serum iron concentrations (SICs) occur two to three hours after therapeutic dosing and four to six hours after ingestion of an overdose [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Absorbed iron is rapidly cleared from the circulation and taken up by the cells of various tissues, where high concentrations of iron disrupt mitochondrial function [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/20,22\">",
"     20,22",
"    </a>",
"    ]. For the most part, entry of iron into the tissues is an active, saturable process; the liver is unique in that it also can passively absorb iron [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Because of the liver's capacity to absorb considerable quantities of iron, the half-life of iron after therapeutic and toxic dosing is similar (approximately six hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no physiologic mechanisms for iron excretion. Iron may be lost via the constant sloughing of intestinal cells, as well as menstrual bleeding in menarchal women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The manifestations of iron toxicity are typically described in five (often overlapping) phases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/12,15-17\">",
"     12,15-17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastrointestinal (GI) phase: 30 minutes to six hours after ingestion",
"     </li>",
"     <li>",
"      Latent, or relative stability, phase: 6 to 24 hours after ingestion",
"     </li>",
"     <li>",
"      Shock and metabolic acidosis: 6 to 72 hours after ingestion",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Hepatotoxicity/hepatic",
"      </span>",
"      necrosis: 12 to 96 hours after ingestion",
"     </li>",
"     <li>",
"      Bowel obstruction: two to eight weeks after ingestion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The progression of these phases may occur rapidly depending on the severity of the ingestion. The clinical phase should therefore be determined by the patient's clinical and laboratory manifestations, not by the time since the ingestion. Each phase is described in detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Gastrointestinal phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gastrointestinal (GI) phase occurs between 30 minutes and 6 hours after ingestion. The clinical manifestations of this phase are the result of direct injury to the GI mucosa. Signs and symptoms may include abdominal pain, vomiting, diarrhea, hematemesis, melena, lethargy, shock (from capillary leak and third spacing), and metabolic acidosis. Vomitus and stools may be dark gray, green or black due to the presence of disintegrating iron tablets. Vomiting is the most sensitive indicator of serious ingestions. Death in this phase is usually caused by hypovolemic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients with mild to moderate iron toxicity do not progress beyond this phase and their symptoms may actually resolve within four to six hours. If no gastrointestinal symptoms develop within six hours of a presumed iron ingestion, it is unlikely that iron toxicity will occur. Ingestion of enteric-coated iron tablets is an exception to the \"six hour rule\".",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Latent phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The latent phase (sometimes also referred to as the \"relative stability\" or \"quiescent phase\") occurs from 6 to 24 hours after ingestion and is a period of apparent recovery. The resolution of GI symptoms is presumed to occur as circulating free iron is redistributed into the reticuloendothelial systems.",
"   </p>",
"   <p>",
"    This phase may be transient or may not appear at all in patients with severe iron poisoning. Patients appear stable, but they may not be asymptomatic. Careful evaluation may reveal poor perfusion, hyperventilation (secondary to metabolic acidosis), and oliguria (secondary to hypovolemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is critical to differentiate patients who are in this phase from those with low toxicity ingestions who have exhibited only mild gastrointestinal symptoms and for whom toxicity has now resolved. Patients whose GI symptoms have improved should be observed and reevaluated to determine whether they have truly recovered or are progressing to further clinical deterioration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Shock and metabolic acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular toxicity (manifested as shock, pallor, tachycardia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypotension) may develop. Coagulopathy (preceding liver dysfunction) can occur because of iron's effect (as a protease inhibitor) on prothrombin [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology of the shock state may be hypovolemic, distributive, or cardiogenic, depending on the time of onset [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypovolemic shock, due to fluid and blood losses, occurs within the first few hours.",
"     </li>",
"     <li>",
"      Distributive shock develops a few hours later. The etiology is poorly understood. Decreased vascular tone and increased vascular permeability may be caused primarily by iron or possibly ferritin.",
"     </li>",
"     <li>",
"      Cardiogenic shock develops within 24 to 48 hours after the ingestion due to the depressant effect of iron on myocardial cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Metabolic acidosis is often profound and is an indicator of iron-induced toxicity. It is caused, at least in part, by hydration of absorbed ferric ions, which releases three protons (Fe3+ &nbsp;+ &nbsp;3H2O &nbsp;&mdash;&gt; &nbsp;Fe(OH)3 &nbsp;+ &nbsp;3H+) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/18\">",
"     18",
"    </a>",
"    ]. Lactic acidosis may also occur as the result of",
"    <span class=\"nowrap\">",
"     hypovolemia/poor",
"    </span>",
"    tissue perfusion and iron-induced mitochondrial dysfunction.",
"   </p>",
"   <p>",
"    The following clinical features, leading to multisystem organ failure, can be seen in the shock and metabolic acidosis phase:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastrointestinal hemorrhage, with hematemesis and melena, may recur. Bowel perforation may develop.",
"     </li>",
"     <li>",
"      Progressive pulmonary dysfunction (acute lung injury or the acute respiratory distress syndrome) is a distinguishing characteristic of this phase. The etiology likely includes free radical production causing capillary leak, along with hypotension and metabolic acidosis.",
"     </li>",
"     <li>",
"      An iron-induced coagulopathy may worsen bleeding and hypovolemia.",
"     </li>",
"     <li>",
"      Renal and neurologic dysfunction can develop during this phase.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients may develop jaundice, coma, and worsening coagulopathy from hepatic dysfunction. Death in this third phase is caused by widespread cellular dysfunction, which results from mitochondrial disruption [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/25\">",
"     25",
"    </a>",
"    ]. Once a critical amount of iron has reached the mitochondria, therapy has little effect and outcome is poor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hepatotoxicity/hepatic necrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of hepatotoxicity is usually within two days of ingestion. Although hepatic necrosis does not occur in all iron-poisoned patients, it may develop within 12 to 96 hours after ingestion. The liver is particularly vulnerable to iron toxicity for several reasons. It is exposed to high concentrations of iron through the portal circulation, it absorbs iron passively, and hepatocytes have high metabolic activity. Liver failure is the second most common cause of death from iron poisoning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Bowel obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bowel obstruction occurs as the result of GI scarring. Symptoms typically develop two to eight weeks after the ingestion. The classic location for GI obstruction is the gastric outlet, since this is where iron tablets aggregate and damage tissue, with subsequent scar tissue formation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/18,28\">",
"     18,28",
"    </a>",
"    ]. Vomiting is the presenting symptom of this late sequela.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other agents that can cause vomiting with toxic ingestion include salicylates, caustic agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    , isopropanol, arsenic and mercurial salts, nonsteroidal anti-inflammatory drugs (NSAIDs), organophosphorus compounds, nicotine carbamates, mushrooms, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron poisoning is primarily a clinical diagnosis. A combination of history, physical examination, and laboratory features can identify patients at risk for systemic toxicity. These may include signs or symptoms of a severe overdose (such as severe, persistent vomiting and diarrhea, hypovolemia, altered mental status, and unexplained metabolic acidosis) or more subtle indications of volume depletion and metabolic acidosis (such as tachycardia, lethargy, or tachypnea). All of these patients require aggressive supportive care and treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following historical information is essential for determining the significance of an iron ingestion and directing further management:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      What type of iron was taken and how much? One determinant of the severity of an overdose is the",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of elemental iron that was ingested and the formulation of iron. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Iron preparations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Toxic dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When did the ingestion occur? Symptoms of iron intoxication generally develop soon after the ingestion. Patients who have not developed symptoms within six hours are unlikely to have ingested a significant amount of iron, unless they have ingested an enteric-coated preparation.",
"     </li>",
"     <li>",
"      Was the ingestion unintentional or intentional? An intentional ingestion, whether as a suicide",
"      <span class=\"nowrap\">",
"       attempt/gesture",
"      </span>",
"      or as a form of child abuse, is more likely to be significant [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Intentional ingestion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Did the patient have access to other toxic substances? For children, are there other children at home who could have also ingested iron [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/16\">",
"       16",
"      </a>",
"      ]?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who require resuscitation must be rapidly identified and appropriate treatment (including airway protection, respiratory support, and volume resuscitation) must be initiated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=see_link&amp;anchor=H4#H4\">",
"     \"Approach to the child with occult toxic exposure\", section on 'Initial evaluation and stabilization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physical findings typical for a severe iron overdose include tachycardia, poor peripheral perfusion, altered mental status, and hypotension, all indicators of shock. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28948?source=see_link\">",
"     \"Assessment of perfusion in pediatric resuscitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subtle findings, including signs of poor perfusion (such as lethargy and tachycardia), metabolic acidosis (tachypnea), or gastrointestinal (GI) symptoms (abdominal tenderness, persistent vomiting, or diarrhea) may identify a patient with a significant ingestion who has progressed to the latent phase. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Latent phase'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purpose of the laboratory evaluation is to confirm the diagnosis of iron poisoning and to monitor for clinical effects (such as metabolic acidosis, liver damage, coagulopathy, and anemia). Laboratory evaluation for iron intoxication should be performed for any child with signs of systemic toxicity, ingestion of an uncertain amount of iron,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an ingestion of more than 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of elemental iron [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory testing should include [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/3,12\">",
"     3,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum iron concentration (performed urgently if possible)",
"     </li>",
"     <li>",
"      Electrolytes, blood urea nitrogen (BUN), and glucose",
"     </li>",
"     <li>",
"      Aminotransferases and bilirubin",
"     </li>",
"     <li>",
"      ABG in moderately and severely poisoned patients",
"     </li>",
"     <li>",
"      Complete blood count with differential",
"     </li>",
"     <li>",
"      Prothrombin and partial thromboplastin time",
"     </li>",
"     <li>",
"      Type and crossmatch",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Serum iron concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of serum iron concentration (SIC) is useful for confirming the diagnosis of iron ingestion. It may be helpful in predicting serious toxicity only if blood samples are drawn at the appropriate time. It cannot always be correlated with the severity or the clinical phase of iron intoxication because it measures free iron circulating in the blood. It is intracellular iron that causes systemic toxicity.",
"   </p>",
"   <p>",
"    The best estimate of the severity of the overdose can be determined by performing a SIC measurement within four to six hours of the ingestion. For slow-release iron, a SIC should be obtained at eight hours [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Because iron is rapidly cleared from the serum, concentrations obtained after eight hours may be deceivingly low.",
"   </p>",
"   <p>",
"    Peak serum iron concentrations typically correlate with the following levels of toxicity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Less than 350",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (63",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      &ndash; Minimal toxicity.",
"     </li>",
"     <li>",
"      Between 350 and 500",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (63 and 90",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      &ndash; Mild to moderate GI symptoms (rarely develop serious complications) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Greater than 500",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (90",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      &ndash; Serious systemic toxicity.",
"     </li>",
"     <li>",
"      Greater than 1000",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (179",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      &ndash; Significant morbidity and mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/12,16,17,30,31\">",
"       12,16,17,30,31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several retrospective series have reported patients with SIC greater than 500",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (90",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    who were asymptomatic, as well as patients with cardiovascular instability with SIC less than 500",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (90",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/15,30,31\">",
"     15,30,31",
"    </a>",
"    ]. These lower levels may not have represented peak serum iron concentrations. Although iron is rapidly absorbed, absorption from the ingestion of sustained-release tablets, enteric-coated tablets, or ongoing release of iron from concretions of pills may be delayed. These reports illustrate the fact that there is no test (including SIC) that is superior to the clinical status of the patient for determining the severity of an iron ingestion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Total iron binding capacity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total serum iron binding capacity (TIBC) cannot be used to manage patients with iron overdose [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/9\">",
"     9",
"    </a>",
"    ]. TIBC measures the amount of iron in the blood that is bound to transferrin. In theory, there should be no free iron when TIBC is greater than SIC. However, laboratory methods used to measure TIBC are inaccurate in patients with iron overdose. In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    interferes with the measurement of TIBC. Finally, multiple case reports have described iron toxicity in cases where the TIBC was greater than SIC [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/30,32,33\">",
"     30,32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;An anion gap metabolic acidosis is an important, but nonspecific, predictor of iron toxicity. Although leukocytosis (WBC more than 15,000",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    and hyperglycemia (greater than 150",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    are associated with serum iron levels greater than 300",
"    <span class=\"nowrap\">",
"     mcg/dL,",
"    </span>",
"    they are nonspecific [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. More importantly, the absence of leukocytosis or hyperglycemia CANNOT be used to exclude iron toxicity. Other tests that are useful for monitoring the course of treatment include electrolytes, BUN, creatinine, liver function tests, prothrombin time, and partial thromboplastin time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Radiographic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who may have ingested more than 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of elemental iron or who have significant symptoms should receive a plain radiograph of the abdomen. The presence of radiopaque pills in the stomach confirms the ingestion of iron (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68584 \" href=\"UTD.htm?27/43/28350\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The radiopacity of iron tablets depends on the type of formulation and content of elemental iron. Many liquid iron preparations and chewable vitamins with iron (which have low concentrations of iron) are not visible. Consequently, the presence of few or no pills does not necessarily mean that the ingestion was insignificant. This was demonstrated in a retrospective review describing 93 children with iron ingestions (55 percent chewable tablets, 40 percent nonchewable tablets). Abdominal radiographs were obtained in 54 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/36\">",
"     36",
"    </a>",
"    ]. Radiopaque densities were visualized in only one case.",
"   </p>",
"   <p>",
"    Patients with a significant iron overdose who have no radiopaque pills seen on plain radiograph are unlikely to benefit from gastric decontamination [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'GI decontamination'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Deferoxamine challenge test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    challenge test (DFO) is no longer advocated as a method to confirm the ingestion of a toxic dose of iron.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     Deferoxamine",
"    </a>",
"    binds free iron creating ferrioxamine which is excreted in the urine. Urine containing ferrioxamine may be brick orange or \"vin ros&eacute;\". The DFO challenge test consisted of administering an intramuscular dose of DFO and waiting to see if the patient developed \"vin ros&eacute;\" urine. Multiple reports have identified patients with a SIC greater than 500",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    whose urine did not change color with deferoxamine [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients who have ingested toxic amounts of iron begins with aggressive supportive care. Decontamination with whole bowel irrigation may be helpful. Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    to increase iron excretion is indicated for patients with severe toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airway protection and respiratory support should be provided as needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=see_link&amp;anchor=H4#H4\">",
"     \"Approach to the child with occult toxic exposure\", section on 'Initial evaluation and stabilization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Volume resuscitation to maintain euvolemia is essential. Hypovolemic shock is the major cause of mortality during the first phase of iron intoxication. Patients who present with severe gastrointestinal (GI) phase symptoms require urgent intensive management to maintain effective circulating blood volume [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/3,25\">",
"     3,25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Gastrointestinal phase'",
"    </a>",
"    above.) Intravenous access should be obtained. Normal saline should be administered in boluses of 20",
"    <span class=\"nowrap\">",
"     cc/kg",
"    </span>",
"    as necessary to improve perfusion, tachycardia and maintain blood pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=see_link\">",
"     \"Hypovolemic shock in children: Initial evaluation and management\"",
"    </a>",
"    .) Meticulous monitoring and supportive care must continue throughout the duration of treatment.",
"   </p>",
"   <p>",
"    Patients who require supportive care as the result of iron ingestion are likely experiencing significant toxicity. Further evaluation and treatment are necessary. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Evaluation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H30\">",
"     'Deferoxamine'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H29\">",
"     'GI decontamination'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Risk for systemic toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients at risk for systemic toxicity should receive treatment to limit further absorption of iron. Indications of potential serious toxicity include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ingestion of greater than 60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of elemental iron",
"     </li>",
"     <li>",
"      Peak SIC greater than 500",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (90",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Persistent serious symptoms such as vomiting, diarrhea,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      altered mental status",
"     </li>",
"     <li>",
"      Systemic symptoms, including subtle symptoms that can be seen in the latent phase, such as tachycardia, poor perfusion, tachypnea,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypotension (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Latent phase'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Significant number of radiopaque pills on a plain radiograph of the abdomen",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    SIC may not be emergently available at some institutions. In this situation, the decision to proceed with aggressive GI decontamination",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    initiate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    therapy must be made based on the amount of elemental iron ingested, presence of systemic symptoms, and findings on abdominal radiograph. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'GI decontamination'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H30\">",
"     'Deferoxamine'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Systemic symptoms must be distinguished from local GI symptoms. Many patients with SIC less than 500",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (90",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    may have some abdominal pain, vomiting,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diarrhea as the result of GI irritation. In contrast to systemic symptoms, local symptoms generally do not require fluid resuscitation, although smaller children may develop significant, protracted vomiting and diarrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     GI decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;GI decontamination removes iron from the intestine before absorption and tissue uptake can occur. It should be performed for patients with a significant number of radiopaque pill fragments identified on abdominal radiograph [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decisions regarding the optimal intervention are complicated by factors that include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many patients have already vomited, reducing the need for further gastric emptying.",
"     </li>",
"     <li>",
"      Many adult iron preparations are too large to be removed from the holes in an orogastric lavage tube, limiting the value of lavage in this setting.",
"     </li>",
"     <li>",
"      Iron is not well adsorbed by charcoal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In most patients, the risk of gastric lavage following iron overdose outweighs the limited benefit. However, gastric lavage with a large-bore orogastric tube may be indicated for patients with intentional overdoses of large amounts of iron who have a large number of visible pills in the stomach on abdominal radiograph. A repeat abdominal radiograph should be obtained to evaluate the efficacy of gastric evacuation and determine whether further decontamination measures are necessary.",
"   </p>",
"   <p>",
"    Whole bowel irrigation (WBI) is an effective method of GI decontamination for serious iron overdose [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/9\">",
"     9",
"    </a>",
"    ]. There are no randomized trials evaluating the efficacy of WBI for this indication. Case reports and case series, however, have described improved outcomes for patients with iron poisoning who received WBI. Most of the patients also received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. Consequently, the effect of WBI, independent of deferoxamine, is difficult to ascertain. On the other hand, there have been no reports of significant complications from WBI. Thus, whole bowel irrigation should be initiated for all patients with a significant number of pills in the gastrointestinal tract visualized by abdominal radiograph.",
"   </p>",
"   <p>",
"    The procedure for performing WBI, as well as the contraindications and complications, is described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=see_link&amp;anchor=H21#H21\">",
"     \"Decontamination of poisoned children\", section on 'Whole bowel irrigation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link&amp;anchor=H18993876#H18993876\">",
"     \"Gastrointestinal decontamination of poisoned adults\", section on 'Whole bowel irrigation'",
"    </a>",
"    .) Serial abdominal radiographs may be useful in determining the efficacy of WBI over a period of time. The endpoints of treatment are improved clinical status, a clear rectal effluent, and the absence of iron tablets or significantly decreased number of tablets seen on repeat abdominal radiograph [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other forms of GI decontamination are NOT indicated for patients with iron overdose:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Syrup of ipecac should not be prescribed.",
"     </li>",
"     <li>",
"      Gastric lavage with bicarbonate or phosphate solutions is no longer recommended because of the large volume of bicarbonate necessary to achieve effect and reports of phosphate poisoning [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/16,44-47\">",
"       16,44-47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gastric lavage with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      is not recommended because of the large volumes required in an overdose to have any appreciable effect.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"       Activated charcoal",
"      </a>",
"      binds iron poorly and is not useful for the management of iron ingestions.",
"     </li>",
"     <li>",
"      Catharsis via the administration of magnesium-containing preparations (eg, milk of magnesia) has been used to decrease iron absorption, but with limited success [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/17,48\">",
"       17,48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Case reports have described surgical removal of iron from the stomach (gastrotomy) for pill concretions that could not be removed with other methods of GI decontamination [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. There are no randomized trials comparing surgical removal with WBI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Deferoxamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     Deferoxamine",
"    </a>",
"    (DFO), administered intravenously, is the antidote of choice for serious iron overdose. It is a chelating agent that, in acute iron intoxication, binds with ferric iron (Fe3+) in the blood to form water-soluble ferrioxamine that is then excreted by the kidneys. Ferrioxamine gives urine the classically described \"vin ros&eacute;\" color, which actually is orange to reddish brown. DFO must be administered early in the treatment of iron overdose because iron moves rapidly from the circulation into cells, where, in acute intoxication, it is not readily accessible for chelation. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Kinetics'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although there are no randomized trials or case-control series in humans evaluating the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    as an antidote for iron overdose, anecdotal reports and case series describe improved clinical outcomes when deferoxamine is administered intravenously [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Studies in dogs have reported dramatically improved survival following lethal iron overdose for animals who received deferoxamine [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Indications for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    include any of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe symptoms",
"      <span class=\"nowrap\">",
"       (hypovolemia/shock,",
"      </span>",
"      <span class=\"nowrap\">",
"       lethargy/coma,",
"      </span>",
"      persistent vomiting or diarrhea)",
"     </li>",
"     <li>",
"      Anion gap metabolic acidosis",
"     </li>",
"     <li>",
"      Peak serum iron concentration greater than 500",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (90",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Significant number of pills on abdominal radiograph",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Dose and duration of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     Deferoxamine",
"    </a>",
"    should be administered intravenously at a continuous rate of 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour IV, which may be increased to a maximum of 35",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour, based on the severity of clinical symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/9\">",
"     9",
"    </a>",
"    ]. Because of the kinetics of iron absorption and the possibility of lung toxicity with prolonged administration of deferoxamine, we suggest administering larger doses of deferoxamine during the first 24 hours of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/55\">",
"     55",
"    </a>",
"    ]. There are no established guidelines for determining the optimum dose of deferoxamine. Consultation with a medical toxicologist",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    regional poison control center is recommended. (See",
"    <a class=\"local\" href=\"#H39\">",
"     'Additional resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Recommendations for duration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    therapy have used resolution of clinical symptoms such as metabolic acidosis and shock as the endpoint for stopping therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/9,37\">",
"     9,37",
"    </a>",
"    ]. However, such nonspecific guidelines may result in prolonged treatment and increase the risk of lung toxicity from deferoxamine [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. We suggest that the decision to stop deferoxamine therapy be made in consultation with a medical toxicologist",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    regional poison control center, taking into consideration the patient's clinical status and, perhaps, serum iron concentration. (See",
"    <a class=\"local\" href=\"#H39\">",
"     'Additional resources'",
"    </a>",
"    below.) The typical duration of therapy is about 24 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant adverse effects of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    therapy include hypotension and the development of acute respiratory distress syndrome (ARDS):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypotension can occur during the initial administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      . This effect appears to be related to rapid infusion and may be caused by histamine release [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/55\">",
"       55",
"      </a>",
"      ]. It can generally be avoided by providing vigorous fluid resuscitation. This is preferable to slowing down the rate of the deferoxamine infusion, which should be avoided whenever possible.",
"     </li>",
"     <li>",
"      The acute respiratory distress syndrome (ARDS) has been reported in patients who have received continuous infusions of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      for 32 to 72 hours or more [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]. The etiology of lung toxicity is unknown. Some investigators have proposed that once iron has been removed from blood, deferoxamine binds with intracellular iron, resulting in cellular damage [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/55\">",
"       55",
"      </a>",
"      ]. Others have challenged this theory and suggest that the ARDS is secondary to the iron toxicity itself and not the deferoxamine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Elimination enhancement",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     Deferoxamine",
"    </a>",
"    remains the primary mode of therapy for patients with severe iron poisoning. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Deferoxamine'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Extracorporeal methods of iron removal (eg, hemodialysis) are limited in effectiveness because they only remove free circulating iron and must be started soon after ingestion before intracellular iron transport occurs. We STRONGLY recommend consultation with a medical toxicologist if extracorporeal iron removal is being considered. (See",
"    <a class=\"local\" href=\"#H39\">",
"     'Additional resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Extracorporeal removal with exchange transfusion or continuous veno-venous hemofiltration has been associated with good outcomes in cases of massive iron overdose where clinical deterioration persisted and serum iron levels remained very high despite administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An 18 month old child ingested a large amount of iron and had rising serum iron levels despite appropriate treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      infusion [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/58\">",
"       58",
"      </a>",
"      ]. The patient received a two-thirds blood volume exchange followed by five hours of plasmapheresis with reduction of serum iron levels from 1362",
"      <span class=\"nowrap\">",
"       micrograms/dL",
"      </span>",
"      (244",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      to 40",
"      <span class=\"nowrap\">",
"       micrograms/dL",
"      </span>",
"      (7.3",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      and clinical improvement.",
"     </li>",
"     <li>",
"      Another 18 month old child, who was fed a large amount of iron by his sibling and developed acute gastrointestinal and neurologic signs of toxicity, had a four hour serum iron level of 3906",
"      <span class=\"nowrap\">",
"       micrograms/dL",
"      </span>",
"      (700",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/59\">",
"       59",
"      </a>",
"      ]. This patient received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      infusion and continuous veno-venous hemofiltration resulting in a decrease in serum iron to 148",
"      <span class=\"nowrap\">",
"       micrograms/dL",
"      </span>",
"      (26.5",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      at 22 hours post-ingestion and improved mental status. Iron concentration in the ultrafiltrate was 3.4",
"      <span class=\"nowrap\">",
"       micromol/L.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These cases demonstrate that exchange transfusion or continuous veno-venous hemofiltration may assist in decreasing serum iron and improving clinical status in patients with massive overdose and life-threatening toxicity. However, these modalities carry a significant risk of complications such as bleeding and hemodynamic instability and should be regarded as novel and unreliable therapies of last resort for iron poisoning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Management decisions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients who have severe symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have ingested toxic amounts of iron is straightforward. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'GI decontamination'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H30\">",
"     'Deferoxamine'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Mildly symptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have ingested nontoxic doses of elemental iron frequently experience mild gastrointestinal symptoms such as abdominal pain, vomiting, and diarrhea. Those with an unintentional overdose of less than 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    elemental iron and a normal physical examination may be observed.",
"   </p>",
"   <p>",
"    SIC, an abdominal radiograph and, perhaps, an arterial or venous pH should be obtained when the amount of elemental iron that has been ingested cannot be determined or is more than 40",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    Patients with mild GI symptoms and SIC less than 500",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (90",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    have been managed successfully without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/60\">",
"     60",
"    </a>",
"    ]. We typically observe and monitor these patients for 6 to 12 hours prior to discharge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Asymptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of asymptomatic patients who have ingested a potentially toxic dose of iron or an unknown dose depends upon the time of presentation, peak SIC, and findings on abdominal radiograph [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/3,39\">",
"     3,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients without symptoms for whom the amount of elemental iron ingested is either more than 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or is unknown should have SIC measured and an abdominal radiograph performed. Management may then proceed as follows:",
"   </p>",
"   <p>",
"    Patients who have a SIC less than 500",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (90",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    and no radiopaque pills on abdominal radiograph should be observed for six hours. They may be discharged if they remain asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron overdose during pregnancy is common, but is unique among overdoses because the fetus is protected from the direct effects of iron. Transplacental iron absorption is a saturable process. Consequently, significant accumulation of fetal iron does not occur. The fetus is at risk only when the mother experiences clinical decompensation, such as hypotension, liver failure, or pulmonary failure. Pregnancy should not change the management of iron poisoning. Indications for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    therapy in pregnant patients are the same as those for other patients. Withholding deferoxamine when it is clinically indicated, out of a misguided notion that it may be toxic to the fetus, is a serious error that may have severe consequences for mother and fetus. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Deferoxamine'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Home management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any patient who may have ingested a toxic amount of iron must be referred to a hospital for evaluation and management. However, an evidence-based consensus guideline for the outpatient management of iron ingestion from the American Association of Poison Control Centers suggests that many children with unintentional ingestions of children's chewable vitamins with iron may be carefully observed at home with appropriate follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/61\">",
"     61",
"    </a>",
"    ]. Children who develop persistent vomiting or diarrhea may need referral to the hospital for evaluation and treatment of dehydration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9897575\">",
"    <span class=\"h2\">",
"     Pitfalls in management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several pitfalls in the management of acute iron poisoning have been identified. These include [",
"    <a class=\"abstract\" href=\"UTD.htm?2/57/2970/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inadequate hydration",
"     </li>",
"     <li>",
"      Failure to recognize patients in the latent phase",
"     </li>",
"     <li>",
"      Inaccurate calculation of dose of elemental iron ingested",
"     </li>",
"     <li>",
"      Excessive reliance on the SIC in management decisions",
"     </li>",
"     <li>",
"      Reliance on the total iron binding capacity (TIBC), abdominal radiograph, or associated laboratory tests (including the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      challenge test) to predict toxicity",
"     </li>",
"     <li>",
"      Inadequate",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      dose",
"     </li>",
"     <li>",
"      Withholding",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      from pregnant patients",
"     </li>",
"     <li>",
"      Discontinuation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      on the basis of urine color alone",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website (",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The morbidity and mortality from iron overdose can be significant, particularly for young children and patients with intentional overdoses. Iron preparations that contain potentially dangerous amounts of elemental iron, such as prenatal vitamins, are readily available. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The toxicity of an iron ingestion is determined by the",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of elemental iron ingested and the type of iron formulation. Prenatal iron preparations have the potential for more serious toxicity than adult and child multivitamin preparations. Carbonyl iron and iron polysaccharide complex formulations have little to no toxicity when ingested in overdose. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Iron preparations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Iron exerts its toxic effect in the free ferric state through the creation of free radicals and lipid peroxidation that cause damage to cells. Protective mechanisms (such as binding to transferrin in the blood and to ferritin within cells) are quickly overwhelmed when there is an overdose. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pharmacology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical features of iron toxicity are typically described in five (often overlapping) phases that are manifestations of the toxic effects of iron. These phases include gastrointestinal (GI) features, a latent phase, shock and metabolic acidosis,",
"      <span class=\"nowrap\">",
"       hepatotoxicity/hepatic",
"      </span>",
"      necrosis, and bowel obstruction. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation of patients who have ingested iron should include the following (",
"      <a class=\"graphic graphic_table graphicRef61711 \" href=\"UTD.htm?8/44/8909\">",
"       table 1",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"local\" href=\"#H17\">",
"       'Evaluation'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Determine the type of iron preparation if possible.",
"     </li>",
"     <li>",
"      Determine how much elemental iron was ingested and when.",
"     </li>",
"     <li>",
"      Identify those who are severely ill or who have subtle features of a significant ingestion.",
"     </li>",
"     <li>",
"      Perform laboratory and radiologic evaluation for patients with systemic symptoms and for those with no or localized symptoms who have ingested greater than 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      or an unknown amount of elemental iron.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that patients with any of the following indications receive intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H30\">",
"       'Deferoxamine'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Severe symptoms (altered mental status, hemodynamic instability, persistent vomiting",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diarrhea)",
"     </li>",
"     <li>",
"      Anion gap metabolic acidosis",
"     </li>",
"     <li>",
"      Peak serum iron concentration (SIC) greater than 500",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (90",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Significant number of pills on abdominal radiograph",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The usual dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      is 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per hour intravenously. We suggest that in cases of severe overdose, higher doses of deferoxamine (up to 35",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per hour) be administered during the first 24 hours of treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A medical toxicologist",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      regional poison control center should be consulted to determine the optimum dose of deferoxamine and duration of therapy. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Dose and duration of treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H39\">",
"       'Additional resources'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with a significant number of radiopaque pills on abdominal radiograph receive gastric lavage",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      whole bowel irrigation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H29\">",
"       'GI decontamination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with mild symptoms (local GI), we suggest that those who have ingested greater than 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      or an unknown amount of elemental iron with a serum iron concentration &lt;500",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (90",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      and no radiopaque pills on x-ray be observed for 6 to 12 hours (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Mildly symptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that asymptomatic patients who have ingested greater than 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      or an unknown amount of elemental iron with a serum iron concentration less than 500",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (90",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      and no radiopaque pills on abdominal radiograph be observed for six hours. They may be discharged if they remain asymptomatic (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Asymptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of iron poisoning for pregnant women is the same as for other patients, including the indications for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      therapy. (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that children with unintentional ingestions of children's chewable vitamins and carbonyl iron be carefully observed at home (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Those with persistent vomiting or diarrhea should be referred for evaluation. (See",
"      <a class=\"local\" href=\"#H38\">",
"       'Home management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/1\">",
"      Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2010 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th Annual Report. Clin Toxicol (Phila) 2011; 49:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/2\">",
"      Morris CC. Pediatric iron poisonings in the United States. South Med J 2000; 93:352.",
"     </a>",
"    </li>",
"    <li>",
"     Osterhoudt, KC, Burns Ewald, M, Shannon, M, et al. Toxicologic emergencies. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher, GR, Ludwig, S, Henretig, FM (Eds), Lippincott Williams and Wilkins, Philadelphia 2006. p.979.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/4\">",
"      Berkovitch M, Livne A, Lushkov G, et al. Acute iron intoxication: significant differences between sexes. Vet Hum Toxicol 1997; 39:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/5\">",
"      Juurlink DN, Tenenbein M, Koren G, Redelmeier DA. Iron poisoning in young children: association with the birth of a sibling. CMAJ 2003; 168:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/6\">",
"      Anderson BD, Turchen SG, Manoguerra AS, Clark RF. Retrospective analysis of ingestions of iron containing products in the united states: are there differences between chewable vitamins and adult preparations? J Emerg Med 2000; 19:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/7\">",
"      Watson WA, Litovitz TL, Rodgers GC Jr, et al. 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2005; 23:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/8\">",
"      Tenenbein M. Unit-dose packaging of iron supplements and reduction of iron poisoning in young children. Arch Pediatr Adolesc Med 2005; 159:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/9\">",
"      Madiwale T, Liebelt E. Iron: not a benign therapeutic drug. Curr Opin Pediatr 2006; 18:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/10\">",
"      Food and Drug Administration, HHS. Iron-containing supplements and drugs; label warning statements and unit-dose packaging requirements; removal of regulations for unit-dose packaging requirements for dietary supplements and drugs. Final rule; removal of regulatory provisions in response to court order. Fed Regist 2003; 68:59714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/11\">",
"      Kroeker S, Minuk GY. Intentional iron overdose: an institutional review. CMAJ 1994; 150:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/12\">",
"      Mills KC, Curry SC. Acute iron poisoning. Emerg Med Clin North Am 1994; 12:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/13\">",
"      Spiller HA, Wahlen HS, Stephens TL, et al. Multi-center retrospective evaluation of carbonyl iron ingestions. Vet Hum Toxicol 2002; 44:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/14\">",
"      Klein-Schwartz W. Toxicity of polysaccharide--iron complex exposures reported to poison control centers. Ann Pharmacother 2000; 34:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/15\">",
"      Klein-Schwartz W, Oderda GM, Gorman RL, et al. Assessment of management guidelines. Acute iron ingestion. Clin Pediatr (Phila) 1990; 29:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/16\">",
"      Morse SB, Hardwick WE Jr, King WD. Fatal iron intoxication in an infant. South Med J 1997; 90:1043.",
"     </a>",
"    </li>",
"    <li>",
"     Velez, L, Delaney, K. Heavy metals. In: Emergency Medicine: Concepts and Clinical Practice, 5th edition, Marx, J, Hockberger, R, Walls, R (Eds), Mosby, St. Louis 2006. p.2418.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/18\">",
"      Tenenbein M. Toxicokinetics and toxicodynamics of iron poisoning. Toxicol Lett 1998; 102-103:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/19\">",
"      Walker SE, Paton TW, Cowan DH, et al. Bioavailability of iron in oral ferrous sulfate preparations in healthy volunteers. CMAJ 1989; 141:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/20\">",
"      Robotham JL, Lietman PS. Acute iron poisoning. A review. Am J Dis Child 1980; 134:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/21\">",
"      Harju E. Clinical pharmacokinetics of iron preparations. Clin Pharmacokinet 1989; 17:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/22\">",
"      Riordan M, Rylance G, Berry K. Poisoning in children 3: common medicines. Arch Dis Child 2002; 87:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/23\">",
"      Fawwaz RA, Winchell HS, Pollycove M, Sargent T. Hepatic iron deposition in humans. I. First-pass hepatic deposition of intestinally absorbed iron in patients with low plasma latent iron-binding capacity. Blood 1967; 30:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/24\">",
"      Zimelman AP, Zimmerman HJ, McLean R, Weintraub LR. Effect of iron saturation of transferrin on hepatic iron uptake: an in vitro study. Gastroenterology 1977; 72:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/25\">",
"      Reynolds LG. Diagnosis and management of acute iron poisoning. Baillieres Clin Haematol 1989; 2:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/26\">",
"      Tenenbein M, Israels SJ. Early coagulopathy in severe iron poisoning. J Pediatr 1988; 113:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/27\">",
"      Rosenmund A, Haeberli A, Straub PW. Blood coagulation and acute iron toxicity. Reversible iron-induced inactivation of serine proteases in vitro. J Lab Clin Med 1984; 103:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/28\">",
"      Tenenbein M, Littman C, Stimpson RE. Gastrointestinal pathology in adult iron overdose. J Toxicol Clin Toxicol 1990; 28:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/29\">",
"      Black J, Zenel JA. Child abuse by intentional iron poisoning presenting as shock and persistent acidosis. Pediatrics 2003; 111:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/30\">",
"      Chyka PA, Butler AY. Assessment of acute iron poisoning by laboratory and clinical observations. Am J Emerg Med 1993; 11:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/31\">",
"      Chyka PA, Butler AY, Holley JE. Serum iron concentrations and symptoms of acute iron poisoning in children. Pharmacotherapy 1996; 16:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/32\">",
"      Siff JE, Meldon SW, Tomassoni AJ. Usefulness of the total iron binding capacity in the evaluation and treatment of acute iron overdose. Ann Emerg Med 1999; 33:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/33\">",
"      Thompson DF. Reassessment of measuring total iron binding capacity in acute iron overdose. Ann Pharmacother 1994; 28:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/34\">",
"      Palatnick W, Tenenbein M. Leukocytosis, hyperglycemia, vomiting, and positive X-rays are not indicators of severity of iron overdose in adults. Am J Emerg Med 1996; 14:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/35\">",
"      Lacouture PG, Wason S, Temple AR, et al. Emergency assessment of severity in iron overdose by clinical and laboratory methods. J Pediatr 1981; 99:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/36\">",
"      Everson GW, Oudjhane K, Young LW, Krenzelok EP. Effectiveness of abdominal radiographs in visualizing chewable iron supplements following overdose. Am J Emerg Med 1989; 7:459.",
"     </a>",
"    </li>",
"    <li>",
"     Tenenbein, M. Iron. In: Clinical Toxicology, Ford, MD, Delaney, KA, Ling, LJ, et al. (Eds), WB Saunders, Philadelphia 2001. p.305.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/38\">",
"      Position paper: whole bowel irrigation. J Toxicol Clin Toxicol 2004; 42:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/39\">",
"      Fine JS. Iron poisoning. Curr Probl Pediatr 2000; 30:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/40\">",
"      Tenenbein M. Whole bowel irrigation in iron poisoning. J Pediatr 1987; 111:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/41\">",
"      Kaczorowski JM, Wax PM. Five days of whole-bowel irrigation in a case of pediatric iron ingestion. Ann Emerg Med 1996; 27:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/42\">",
"      Palatnick W, Tenenbein M. Safety of treating poisoning patients with whole bowel irrigation. Am J Emerg Med 1988; 6:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/43\">",
"      Everson GW, Bertaccini EJ, O'Leary J. Use of whole bowel irrigation in an infant following iron overdose. Am J Emerg Med 1991; 9:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/44\">",
"      Banner W Jr, Tong TG. Iron poisoning. Pediatr Clin North Am 1986; 33:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/45\">",
"      Czajka PA, Konrad JD, Duffy JP. Iron poisoning: an in vitro comparison of bicarbonate and phosphate lavage solutions. J Pediatr 1981; 98:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/46\">",
"      Czajka PA. Effect of bicarbonate, phosphate, and saline lavage solutions on the dissolution of ferrous sulfate tablets. J Toxicol Clin Toxicol 1984; 22:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/47\">",
"      Geffner ME, Opas LM. Phosphate poisoning complicating treatment for iron ingestion. Am J Dis Child 1980; 134:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/48\">",
"      Snyder BK, Clark RF. Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: a randomized controlled trial. Ann Emerg Med 1999; 33:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/49\">",
"      Landsman I, Bricker JT, Reid BS, Bloss RS. Emergency gastrotomy: treatment of choice for iron bezoar. J Pediatr Surg 1987; 22:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/50\">",
"      Foxford R, Goldfrank L. Gastrotomy--a surgical approach to iron overdose. Ann Emerg Med 1985; 14:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/51\">",
"      Tenenbein M. Benefits of parenteral deferoxamine for acute iron poisoning. J Toxicol Clin Toxicol 1996; 34:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/52\">",
"      McEnery JT, Greengard J. Treatment of acute iron ingestion with deferoxamine in 20 children. J Pediatr 1966; 68:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/53\">",
"      Whitten CF, Gibson GW, Good MH, et al. Studies in acute iron poisoning. I. Desferrioxamine in the treatment of acute iron poisoning: clinical observations, experimental studies, and theoretical considerations. Pediatrics 1965; 36:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/54\">",
"      Whitten CF, Chen YC, Gibson GW. Studies in acute iron poisoning. II. Further observations on desferrioxamine in the treatment of acute experimental iron poisoning. Pediatrics 1966; 38:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/55\">",
"      Howland MA. Risks of parenteral deferoxamine for acute iron poisoning. J Toxicol Clin Toxicol 1996; 34:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/56\">",
"      Ioannides AS, Panisello JM. Acute respiratory distress syndrome in children with acute iron poisoning: the role of intravenous desferrioxamine. Eur J Pediatr 2000; 159:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/57\">",
"      Tenenbein M, Kowalski S, Sienko A, et al. Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning. Lancet 1992; 339:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/58\">",
"      Carlsson M, Cortes D, Jepsen S, Kanstrup T. Severe iron intoxication treated with exchange transfusion. Arch Dis Child 2008; 93:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/59\">",
"      Milne C, Petros A. The use of haemofiltration for severe iron overdose. Arch Dis Child 2010; 95:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/60\">",
"      Bosse GM. Conservative management of patients with moderately elevated serum iron levels. J Toxicol Clin Toxicol 1995; 33:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/57/2970/abstract/61\">",
"      Manoguerra AS, Erdman AR, Booze LL, et al. Iron ingestion: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 2005; 43:553.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6498 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-197.136.42.3-1591A33FAF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_57_2970=[""].join("\n");
var outline_f2_57_2970=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H40\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Unintentional ingestion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Intentional ingestion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Iron preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Toxic dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Iron toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Gastrointestinal phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Latent phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Shock and metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hepatotoxicity/hepatic necrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Bowel obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Serum iron concentration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Total iron binding capacity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Other tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Radiographic evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Deferoxamine challenge test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Risk for systemic toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      GI decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Deferoxamine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Dose and duration of treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Elimination enhancement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Management decisions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Mildly symptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Home management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9897575\">",
"      Pitfalls in management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6498\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6498|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/43/28350\" title=\"diagnostic image 1\">",
"      Ferrous sulfate overdose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6498|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/44/8909\" title=\"table 1\">",
"      Acute iron intoxication - Rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/39/14973\" title=\"table 2\">",
"      Elemental iron content",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/44/717\" title=\"table 3\">",
"      Elemental iron in multivitamins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=related_link\">",
"      Approach to the child with occult toxic exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28948?source=related_link\">",
"      Assessment of perfusion in pediatric resuscitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=related_link\">",
"      Decontamination of poisoned children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=related_link\">",
"      Gastrointestinal decontamination of poisoned adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=related_link\">",
"      Hypovolemic shock in children: Initial evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=related_link\">",
"      Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4329?source=related_link\">",
"      Iron requirements and iron deficiency in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37944?source=related_link\">",
"      Prevention of poisoning in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=related_link\">",
"      Regulation of iron balance",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_57_2971="Rules for good sleep PI";
var content_f2_57_2971=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F51203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F51203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ten basic rules for a good night's sleep",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Sleep only as much as you need to feel rested and then get out of bed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Keep a regular sleep schedule",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Avoid forcing sleep",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Exercise regularly for at least 20 minutes, preferably 4 to 5 hours before bedtime",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Avoid caffeinated beverages after lunch",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Avoid alcohol near bedtime: no \"night cap\"",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Avoid smoking, especially in the evening",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Do not go to bed hungry",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Adjust bedroom environment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Deal with your worries before bedtime",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_57_2971=[""].join("\n");
var outline_f2_57_2971=null;
var title_f2_57_2972="Diff dx disagreements";
var content_f2_57_2972=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F73237&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F73237&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis for disagreements between health care providers and families",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Major Reason",
"       </td>",
"       <td class=\"subtitle1\">",
"        Etiology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Response",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Misunderstanding",
"       </td>",
"       <td>",
"        Not informed",
"       </td>",
"       <td>",
"        Give information simply and in small chunks; check in frequently; use visual aids if possible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Given different information",
"       </td>",
"       <td>",
"        Bring providers together and give consistent information",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Affective reasons",
"       </td>",
"       <td>",
"        Stress interferes with understanding",
"       </td>",
"       <td>",
"        Support family; give information again",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Denial",
"       </td>",
"       <td>",
"        Attend to emotions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Guilt",
"       </td>",
"       <td>",
"        Attend to emotions; ask what patient wants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lack of trust",
"       </td>",
"       <td>",
"        Acknowledge; negotiate plan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Other",
"       </td>",
"       <td>",
"        Following patient's wishes",
"       </td>",
"       <td>",
"        Ethics consultation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Secondary gain",
"       </td>",
"       <td>",
"        Confirm facts; ethics consultation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hope for a miracle",
"       </td>",
"       <td>",
"        Religious support",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weighs patient attributes more than physician prediction",
"       </td>",
"       <td>",
"        Explore and try to understand reasoning behind family decisions&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Conflict persists",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Second opinion; ethics or palliative care consultation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_57_2972=[""].join("\n");
var outline_f2_57_2972=null;
var title_f2_57_2973="Adj analgesics cancer pain";
var content_f2_57_2973=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F80423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F80423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Adjuvant analgesics used for cancer pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Category based on conventional use",
"      </td>",
"      <td class=\"subtitle1\">",
"       Class",
"      </td>",
"      <td class=\"subtitle1\">",
"       Subclass",
"      </td>",
"      <td class=\"subtitle1\">",
"       Drugs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"8\">",
"       Multipurpose analgesics",
"      </td>",
"      <td>",
"       Corticosteroids",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       Dexamethasone, prednisone, methylprednisone",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Antidepressants",
"      </td>",
"      <td>",
"       Tricyclic",
"      </td>",
"      <td>",
"       Amitriptyline, desipramine, nortriptyline",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       SNRIs",
"      </td>",
"      <td>",
"       Duloxetine, minalcipran, venlafaxine, desvenlafaxine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       SSRIs",
"      </td>",
"      <td>",
"       Paroxetine, citalopram",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Other",
"      </td>",
"      <td>",
"       Buproprion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Alpha-2 adrenergic agonists",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       Tizanidine, clonidine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cannabinoids",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       Dronabinol, nabilone, others",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Topical analgesics",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       Local anesthetics capsaicin, tricyclic antidepressants, NSAIDs, others",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"7\">",
"       Used for neuropathic pain",
"      </td>",
"      <td>",
"       All multipurpose analgesics",
"      </td>",
"      <td>",
"       See above",
"      </td>",
"      <td>",
"       See above",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Anticonvulsants",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       Gabapentin, pregabalin, valproate, phenytoin, carbamazepine, oxcarbazepine, topiramate, lamotrigine, tiagabine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Sodium channel blockers",
"      </td>",
"      <td>",
"       Sodium channel modulator",
"      </td>",
"      <td>",
"       Lacosamide",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sodium channel blocker",
"      </td>",
"      <td>",
"       Mexiletine, IV lidocaine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N-methyl-D-aspartate receptor antagonists",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       Ketamine, memantine, dextromethorphan, amantadine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       GABA agonists",
"      </td>",
"      <td>",
"       GABA",
"       <sub>",
"        a",
"       </sub>",
"       agonists",
"      </td>",
"      <td>",
"       Clonazepam",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       GABA",
"       <sub>",
"        b",
"       </sub>",
"       agonists",
"      </td>",
"      <td>",
"       Baclofen",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Used for bone pain",
"      </td>",
"      <td rowspan=\"2\">",
"       Osteoclast inhibitors",
"      </td>",
"      <td>",
"       Bisphosphonates",
"      </td>",
"      <td>",
"       Pamidronate, zolendronate, ibandronate",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       Calcitonin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Radiopharmaceuticals",
"       </p>",
"       <p>",
"        Plus: NSAIDs, corticosteroids",
"       </p>",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       Strontium-89, samarium-153",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Used for bowel obstruction",
"      </td>",
"      <td>",
"       Anticholinergic drugs",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       Scopolamine, atropine, glycopyrrolate",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Somatostatin analogue",
"       </p>",
"       <p>",
"        Plus: Corticosteroids",
"       </p>",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       Octreotide",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    GABA: gamma amino butyric acid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_57_2973=[""].join("\n");
var outline_f2_57_2973=null;
var title_f2_57_2974="Asthma and COPD";
var content_f2_57_2974=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Asthma and COPD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 437px; height: 244px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from the Global Initiative for Chronic Obstructive Pulmonary Disease, based on an April 1998 meeting of the National Heart, Lung, and Blood Institute and the World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_57_2974=[""].join("\n");
var outline_f2_57_2974=null;
var title_f2_57_2975="Iron needs during adolescence";
var content_f2_57_2975=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 587px\">",
"   <div class=\"ttl\">",
"    Iron needs during adolescence",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 567px; height: 317px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The figure on the left is based on a representative boy whose peak adolescent growth is at 13.5 years, near the average in the USA. Iron needs peak sharply during the growth spurt but decline rapidly thereafter. Sexual maturation (progression from Tanner stages 2 to 5) begins about 2 years before peak growth; this signals the period of greatest iron needs. The figure on the right is based on a representative girl whose peak growth is at 11.5 years, near the average in the USA. Although iron needs rise to a maximum during peak growth, they remain high subsequently, since the need to replace menstrual iron loss begins about 1 year after peak growth.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Dallman, PR. Changing iron needs from birth through adolescence. In: Nutritional anemias, Fomon, SJ, Zlotkin, S (Ed), Nestle Nutrition Workshop Series, vol 30, Nestec, Ltd. Vevey/Raven Press, Ltd, New York 1992. p. 34.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_57_2975=[""].join("\n");
var outline_f2_57_2975=null;
